{"id":391065,"date":"2025-12-10T03:24:00","date_gmt":"2025-12-09T19:24:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=391065"},"modified":"2025-12-10T03:24:00","modified_gmt":"2025-12-09T19:24:00","slug":"menarini-group-%e6%96%bc-2025-%e5%b9%b4%e8%81%96%e5%ae%89%e6%9d%b1%e5%b0%bc%e5%a5%a7%e4%b9%b3%e7%99%8c%e7%a0%94%e8%a8%8e%e6%9c%83%e5%85%ac%e4%bd%88-elacestrant-orserdu-%e9%87%9d%e5%b0%8d-er","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=391065","title":{"rendered":"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>\u6b64\u5916\uff0celacestrant \u5ee3\u6cdb\u7684\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u6700\u65b0\u9032\u5c55\uff0c\u9032\u4e00\u6b65\u978f\u56fa\u5176\u4f5c\u70ba\u806f\u5408\u6cbb\u7642\u3001\u4ee5\u53ca\u8f49\u79fb\u6027\u548c\u65e9\u671f\u4e73\u764c\u6cbb\u7642\u4e2d\u9aa8\u5e79\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u6f5b\u529b\u3002 <\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\">\u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d04<\/span><span class=\"legendSpanClass\">2025\u5e7412\u670810\u65e5<\/span> \/\u7f8e\u901a\u793e\/ &#8212; \u570b\u969b\u9818\u5148\u7684\u85e5\u696d\u53ca\u8a3a\u65b7\u516c\u53f8 Menarini Group\uff08\u4e0b\u7a31\u300cMenarini\u300d\uff09\uff0c\u8207\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u8b8a\u9769\u6027\u816b\u7624\u7642\u6cd5\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u4e0b\u7a31\u300cStemline\u300d\uff09\uff0c\u5ba3\u4f48\u5c07\u516c\u4f48\u7b2c 2 \u671f ELEVATE \u7814\u7a76\u4e2d\u5169\u9805\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u6700\u65b0\u5177\u81e8\u5e8a\u610f\u7fa9\u7684\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7642\u6548\u7d50\u679c\uff0c\u8a72\u7814\u7a76\u91dd\u5c0d\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u3002ELEVATE \u7814\u7a76\u65e8\u5728\u8a55\u4f30\u5168\u53e3\u670d\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u85c9\u4ee5\u514b\u670d ER+\/HER2- mBC \u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6a5f\u5236\uff0c\u5f9e\u800c\u6539\u5584\u60a3\u8005\u7684\u6cbb\u7642\u6210\u6548\u3002\u76f8\u95dc\u6578\u64da\u5c07\u65bc 12 \u6708 9 \u65e5\u81f3 12 \u65e5\u8209\u884c\u7684 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u767c\u8868\u3002<\/p>\n<p>\u300c\u4ee4\u4eba\u9f13\u821e\u7684\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u589e\u5f37\u4e86\u6211\u5011\u5c0d elacestrant \u5728\u806f\u5408\u6cbb\u7642\u4e2d\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642\u9aa8\u5e79\u89d2\u8272\u7684\u4fe1\u5fc3\u3002\u300d\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821\u5065\u5eb7\u79d1\u5b78\u4e2d\u5fc3\u8840\u6db2\u5b78\/\u816b\u7624\u79d1\u91ab\u5b78\u6559\u6388\u517c\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821 MD \u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u4e73\u764c\u9805\u76ee\u8ca0\u8cac\u4eba Virginia Kaklamani \u91ab\u5b78\u535a\u58eb\u8868\u793a\uff0c\u00a0\u300cElacestrant \u8207 everolimus \u6216 abemaciclib \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u7279\u5fb5\uff0c\u8207\u6bcf\u7a2e\u85e5\u7269\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002\u4e26\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u8a0a\u865f\u3002\u300d<\/p>\n<p>\u5c07\u65bc SABCS \u767c\u8868\u7684 ELEVATE \u6578\u64da\u986f\u793a\uff0c\u5c0d\u65bc\u66fe\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5f8c\u75c5\u60c5\u60e1\u5316\uff08\u4e0d\u8ad6\u662f\u5426\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\uff09\u7684 ER+\/HER2- mBC \u60a3\u8005\uff0celacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u5747\u986f\u793a\u51fa\u4e00\u81f4\u7684 PFS \u6548\u76ca\uff0c\u4e14\u4e0d\u53d7 <i>ESR1<\/i> \u7a81\u8b8a\u72c0\u614b\u5f71\u97ff\u3002\u6700\u65b0\u7d50\u679c\u4ea6\u986f\u793a\uff0c\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8207\u5404\u6a19\u9776\u7642\u6cd5\u52a0\u4e0a\u6a19\u6e96\u8b77\u7406\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u5df2\u77e5\u5b89\u5168\u6027\u4e00\u81f4\u3002<\/p>\n<p><b>\u7b2c 2 \u671f mPFS\uff08\u6708\uff09\uff0895% \u7f6e\u4fe1\u5340\u9593 [CI]\uff09\uff0c\u6db5\u84cb\u6240\u6709\u60a3\u8005\u53ca\u4e9e\u7d44<\/b><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prntar prncbts prnbrbrs prnbbbs prnbsbls\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>\u60a3\u8005\u7fa4\u9ad4<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21<\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>+ Everolimus 7.5mg \u6bcf\u65e5\u4e00\u6b21<\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n = 50)<\/b><\/span><\/p>\n<\/td>\n<td class=\"prngen3\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21<\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>+ Abemaciclib 150 mg \u6bcf\u65e5\u5169\u6b21<\/b><\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>(n = 60)<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">\u6240\u6709\u60a3\u8005<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml40\"><span class=\"prnews_span\"><b>8.3 <\/b>[4.0 \u2013 10.2]<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>14.3 <\/b>[7.3-16.6]<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">\u5167\u81df\u8f49\u79fb<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml40\"><span class=\"prnews_span\"><b>7.7 <\/b>[3.8 \u2013 9.4]<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>14.3 <\/b>[7.4-16.6]<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">\u672a\u66fe\u63a5\u53d7 fulvestrant \u6cbb\u7642<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml40\"><span class=\"prnews_span\"><b>8.3 <\/b>[4.2 \u2013 12.9]<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>14.8 <\/b>[8.7-NR]<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">\u7121\u539f\u767c\u6027\u5167\u5206\u6ccc\u6297\u85e5\u6027<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml40\"><span class=\"prnews_span\"><b>8.3 <\/b>[4.0-12.9]<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><b>14.3 <\/b>[7.3-16.6]<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>ESR1<\/i>\u7a81\u8b8a<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml40\"><span class=\"prnews_span\"><b>8.7 <\/b>[3.5 \u2013 12.9]<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">*<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>ESR1<\/i>\u91ce\u751f\u578b<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml40\"><span class=\"prnews_span\"><b>9.0 <\/b>[4.2 \u2013 12.7]<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">*<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>PIK3CA<\/i>\u7a81\u8b8a<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml40\"><span class=\"prnews_span\"><b>8.3 <\/b>[3.6 &#8211; 10.2]<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">*<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>PIK3CA<\/i>\u91ce\u751f\u578b<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml40\"><span class=\"prnews_span\"><b>9.6 <\/b>[5.6 &#8211; NR]<\/span><\/p>\n<\/td>\n<td class=\"prngen5\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">*<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prntal prnsbtb1 prnbrbrs prnbbbs prnbsbls\" colspan=\"3\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><i>*Elacestrant + abemaciclib \u968a\u5217\u4e2d\u7684\u57fa\u56e0\u7d44\u4e9e\u7d44 (ESR1 \/ PIK3CA) \u4e4b PFS \u5c1a\u672a\u6210\u719f (95% CI)\u3002<\/i><\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p>\u300cElacestrant \u64c1\u6709\u5ee3\u6cdb\u7684\u8b49\u64da\u652f\u6301\uff0c\u6db5\u84cb\u4e86\u6211\u5011\u95dc\u9375 EMERALD \u7814\u7a76\u4e2d\u7684\u55ae\u85e5\u6cbb\u7642\u8a2d\u5b9a\uff08\u73fe\u66f4\u6709\u5169\u4efd\u8fd1\u671f\u767c\u8868\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u6587\u737b\u652f\u6301<sup>[1], [2]<\/sup>\uff09\uff0c\u4ee5\u53ca\u5982 SABCS \u767c\u8868\u6578\u64da\u6240\u5f37\u8abf\uff0c\u5176\u5728\u806f\u5408\u6cbb\u7642\u65b9\u6848\u4e2d\u65e5\u76ca\u589e\u9577\u7684\u6f5b\u529b\u3002\u300dMenarini Group \u884c\u653f\u7e3d\u88c1 <span class=\"xn-person\">Elcin Barker Ergun<\/span> \u8868\u793a\uff0c\u300c\u6211\u5011\u81f4\u529b\u900f\u904e\u591a\u9805\u91dd\u5c0d\u65e9\u671f\u53ca\u8f49\u79fb\u6027\u4e73\u764c\u7684\u9032\u884c\u4e2d\u8a66\u9a57\uff0c\u5168\u9762\u63a2\u7d22 elacestrant \u7684\u6f5b\u5728\u6548\u76ca\u3002\u300d<\/p>\n<p>\u6b64\u5916\uff0c\u5176\u4ed6 elacestrant \u7684\u66f4\u65b0\u8cc7\u8a0a\u4ea6\u5c07\u65bc SABCS \u767c\u8868\uff0c\u63a2\u8a0e\u5176\u5728\u5404\u985e\u4e73\u764c\u6cbb\u7642\u4e2d\u7684\u6f5b\u529b\uff1a<\/p>\n<p><b>\u7c21\u5831\u984c\u76ee\uff1a<\/b>Elacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u6cbb\u7642 ER+\/HER2- \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\uff1aELEVATE \u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\u7684\u7b2c 2 \u671f\u7d50\u679c<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>1255<br \/><b>\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 1:00 \u2013 2:00<br \/><b>\u5730\u9ede\uff1a<\/b>Hemisfair 1-2 <br \/><b>\u767c\u8868\u6f14\u8b1b\u8005\uff1a<\/b> <span class=\"xn-person\">Hope S. Rugo<\/span><\/p>\n<p><b>\u7c21\u5831\u984c\u76ee\uff1a<\/b>Elacestrant \u55ae\u85e5\u6216\u806f\u5408 triptorelin \u6cbb\u7642 ER+\/HER2- \u65e9\u671f\u4e73\u764c\u7d55\u7d93\u524d\u5973\u6027\uff1aSOLTI-2104-Premi\u00c8Re \u7b2c 2 \u671f\u8a66\u9a57\u7684\u4e3b\u8981\u5206\u6790<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>1123<br \/><b>\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0a\u5348 7:30 \u2013 7:33<br \/><b>\u5730\u9ede\uff1a<\/b>301 ABC<br \/><b>\u767c\u8868\u6f14\u8b1b\u8005\uff1a<\/b>Mertixell Bellet<\/p>\n<p><b>\u7c21\u5831\u984c\u76ee\uff1a<\/b>ELEGANT\uff1a\u4e00\u9805\u5728\u5168\u7403\u591a\u4e2d\u5fc3\u9032\u884c\u7684\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\uff0c\u6bd4\u8f03 Elacestrant \u8207\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5728\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c (eBC) \u5973\u6027\u53ca\u7537\u6027\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>1276<br \/><b>\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00<br \/><b>\u5730\u9ede\uff1a<\/b>Henry B. Convention Center<br \/><b>\u767c\u8868\u6f14\u8b1b\u8005\uff1a<\/b>Aditya Bardia<\/p>\n<p><b>\u7c21\u5831\u984c\u76ee\uff1a<\/b> ADELA \u7814\u7a76\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u6bd4\u8f03 Elacestrant (ELA) + Everolimus (EVE) \u5c0d\u6bd4 ELA + \u5b89\u6170\u5291 (PBO) \u5728\u66fe\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u53ca CDK4\/6 \u6291\u5236\u5291\u5f8c\u75c5\u60c5\u60e1\u5316\u4e14\u5e36\u6709 ESR1 \u7a81\u8b8a\u816b\u7624\u7684 ER+\/HER2- \u665a\u671f\u4e73\u764c (aBC) \u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>1141<br \/><b>\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2025 \u5e74 12 \u6708 10 \u65e5\uff08\u661f\u671f\u4e09\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00<br \/><b>\u5730\u9ede\uff1a<\/b>Henry B. Convention Center<br \/><b>\u767c\u8868\u6f14\u8b1b\u8005\uff1a<\/b><span class=\"xn-person\">Antonio Llombart-Cussac<\/span><\/p>\n<p><b>\u7c21\u5831\u984c\u76ee\uff1a<\/b>ERADICATE\uff1a\u4e00\u9805\u7b2c Ib\/II \u671f\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u806f\u5408 trastuzumab deruxtecan \u6cbb\u7642\u5c0d CDK4\/6 \u6291\u5236\u5291\u53ca\u5167\u5206\u6ccc\u6cbb\u7642\u7522\u751f\u6297\u85e5\u6027\u7684 HR+\/HER2-\u4f4e\u8868\u9054 (low) \u6216 HER2-\u8d85\u4f4e\u8868\u9054 (ultralow) \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002<br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>2119<br \/><b>\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00<br \/><b>\u5730\u9ede\uff1a<\/b> Henry B. Convention Center<br \/><b>\u767c\u8868\u6f14\u8b1b\u8005\uff1a<\/b><span class=\"xn-person\">Sara L. Sammons<\/span><\/p>\n<p><b>\u7c21\u5831\u984c\u76ee\uff1a<\/b>\u8853\u524d\u63a5\u53d7 Elacestrant \u53ca PULSAR \u81ea\u9069\u61c9\u653e\u5c04\u6cbb\u7642\u7684\u8377\u723e\u8499\u53d7\u9ad4 (HR) \u967d\u6027 HER2 \u9670\u6027\u4e73\u764c\u60a3\u8005\uff1a\u4e00\u9805\u7b2c II \u671f\u7814\u7a76 (HELP \u8a66\u9a57) <br \/><b>\u6458\u8981\u7de8\u865f\uff1a<\/b>1071<br \/><b>\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a<\/b>2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00<br \/><b>\u5730\u9ede\uff1a<\/b>Henry B. Convention Center<br \/><b>\u767c\u8868\u6f14\u8b1b\u8005\uff1a<\/b><span class=\"xn-person\">Luca Visani<\/span><\/p>\n<p><b>\u95dc\u65bc Elacestrant Clinical Development Program<\/b><\/p>\n<p>\u6b64\u5916\uff0c\u8a72\u516c\u53f8\u4e5f\u8d0a\u52a9\u591a\u9805\u8f49\u79fb\u6027\u4e73\u764c\u7684\u81e8\u5e8a\u8a66\u9a57\uff0c\u63a2\u8a0e elacestrant \u55ae\u7368\u6216\u7d50\u5408\u5176\u4ed6\u7642\u6cd5\u7684\u6cbb\u7642\u3002ELEVATE (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05563220\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT05563220<\/a>) \u662f\u7b2c <span class=\"xn-money\">1b<\/span>\/2 \u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 alpelisib\u3001everolimus\u3001capivasertib\u3001palbociclib\u3001ribociclib \u6216 abemaciclib \u7684\u5b89\u5168\u8207\u7642\u6548\u3002ELECTRA (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05386108\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT05386108<\/a>) \u662f\u7b2c <span class=\"xn-money\">1b<\/span>\/2 \u671f\u3001\u958b\u653e\u6a19\u7c64\u517c\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 abemaciclib \u670d\u7528\uff0c\u5c0d ER+ \u548c HER2- \u4e73\u764c\u60a3\u8005\u7684\u6548\u679c\u3002\u7b2c 2 \u968e\u6bb5\u5247\u8a55\u4f30\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6cbb\u7642\u65b9\u6848\u3002ELCIN (<a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05596409\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT05596409<\/a>) \u662f\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u5c0d ER+ \u548c HER2- \u665a\u671f\/\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\u3002\u9019\u4e9b\u60a3\u8005\u66fe\u63a5\u53d7\u4e00\u81f3\u5169\u7a2e\u8377\u723e\u8499\u7642\u6cd5\uff0c\u4f46\u5728\u8f49\u79fb\u6027\u60c5\u6cc1\u4e2d\uff0c\u672a\u66fe\u670d\u7528 CDK4\/6 \u6291\u5236\u5291\u3002ADELA (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06382948?cond=Breast%20Cancer&amp;term=Elacestrant%20&amp;limit=25&amp;page=1&amp;rank=12\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">NCT06382948<\/a>) \u662f\u7b2c 3 \u671f\u3001\u96a8\u6a5f\u517c\u96d9\u76f2\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 everolimus \u6cbb\u7642 ER+ \u548c HER2- mBC \u53ca ESR1-mut \u816b\u7624\u60a3\u8005\u7684\u7642\u6548\u3002Elacestrant \u4e5f\u65bc\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\uff0c\u70ba\u8f49\u79fb\u6027\u4e73\u764c\u548c\u65e9\u671f\u75be\u75c5\u9032\u884c\u8a55\u4f30\u3002<\/p>\n<p><b>\u95dc\u65bc ORSERDU (elacestrant)<br \/>\u5728\u7f8e\u570b\u6838\u51c6\u7684\u9069\u61c9\u75c7\uff1a<\/b>ORSERDU (elacestrant) \u662f 345 \u6beb\u514b\u7247\u5291\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u6216\u96cc\u6fc0\u7d20\u53d7\u9ad4 <i>(ESR1)<\/i> \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u517c\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u65bc\u63a5\u53d7\u81f3\u5c11\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u9032\u5c55\u3002<\/p>\n<p>\u5982\u6b32\u4e86\u89e3\u7f8e\u570b\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u6599\uff0c\u8acb\u700f\u89bd <a href=\"http:\/\/www.orserdu.com\/\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.orserdu.com<\/a>\u3002<\/p>\n<p><b>\u91cd\u8981\u5b89\u5168\u8cc7\u8a0a<\/b><br \/><i>\u8b66\u544a\u548c\u6ce8\u610f\u4e8b\u9805<\/i><\/p>\n<p><i>\u9ad8\u8102\u8840\u75c7<\/i>\uff1a\u670d\u7528 ORSERDU \u7684\u60a3\u8005\u4e2d\uff0c\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 30% \u548c 27%\u3002\u7b2c 3 \u7d1a\u548c\u7b2c 4 \u7d1a\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 0.9% \u548c 2.2%\u3002\u958b\u59cb\u670d\u7528 ORSERDU \u524d\u548c\u670d\u7528\u671f\u9593\uff0c\u5b9a\u671f\u76e3\u6e2c\u8840\u8102\u72c0\u6cc1\u3002<\/p>\n<p><i>\u80da\u80ce-\u80ce\u5152\u6bd2\u6027<\/i>\uff1a\u6839\u64da\u52d5\u7269\u5be6\u9a57\u7d50\u679c\u53ca\u7576\u4e2d\u4f5c\u7528\u6a5f\u5236\uff0c\u5b55\u5a66\u670d\u7528 ORSERDU\uff0c\u53ef\u80fd\u5c0d\u80ce\u5152\u9020\u6210\u50b7\u5bb3\u3002\u8acb\u544a\u77e5\u5b55\u5a66\u548c\u80b2\u9f61\u5973\u6027\uff0c\u80ce\u5152\u53ef\u80fd\u9762\u5c0d\u7684\u98a8\u96aa\u3002\u5efa\u8b70\u80b2\u9f61\u5973\u6027\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u548c\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002\u5efa\u8b70\u6709\u751f\u80b2\u80fd\u529b\u5973\u6027\u4f34\u4fb6\u7684\u7537\u6027\u60a3\u8005\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002<\/p>\n<p><i>\u4e0d\u826f\u53cd\u61c9<\/i><\/p>\n<p>12% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\uff0c\u51fa\u73fe<i>\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9<\/i>\u3002\u5728\u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0c\u8d85\u904e 1% \u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u808c\u8089\u9aa8\u9abc\u75bc\u75db (1.7%) \u548c\u5641\u5fc3 (1.3%)\u30021.7% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u51fa\u73fe\u81f4\u547d\u7684\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u5fc3\u81df\u9a5f\u505c\u3001\u6557\u8840\u6027\u4f11\u514b\u3001\u61a9\u5ba4\u708e\u548c\u539f\u56e0\u4e0d\u660e\u7684\u60c5\u6cc1\uff08\u5404\u4e00\u4f8b\uff09\u3002<br \/><i>ORSERDU \u6700\u5e38\u898b\u7684\u4e0d\u826f\u53cd\u61c9 (<u>&gt;<\/u> 10%)<\/i>\uff0c\u5305\u62ec\u5be6\u9a57\u5ba4\u7570\u5e38\uff0c\u662f\u808c\u8089\u9aa8\u9abc\u75bc\u75db (41%)\u3001\u5641\u5fc3 (35%)\u3001\u81bd\u56fa\u9187\u5347\u9ad8 (30%)\u3001AST \u589e\u52a0 (29%)\u3001\u7518\u6cb9\u4e09\u916f\u589e\u52a0 (27%)\u3001\u75b2\u52de (26%)\u3001\u8840\u7d05\u86cb\u767d\u4e0b\u964d (26%)\u3001\u5614\u5410 (19%)\u3001ALT \u589e\u9ad8 (17%)\u3001\u9209\u964d\u4f4e (16%)\u3001\u808c\u9178\u589e\u52a0 (16%)\u3001\u98df\u617e\u4e0b\u964d (15%)\u3001\u8179\u7009 (13%)\u3001\u982d\u75db (12%)\u3001\u4fbf\u79d8 (12%)\u3001\u8179\u75db (11%)\u3001\u6f6e\u71b1 (11%) \u548c\u6d88\u5316\u4e0d\u826f (10%)\u3002<\/p>\n<p><i>\u85e5\u7269\u4ea4\u4e92\u53cd\u61c9<\/i><\/p>\n<p><i>\u540c\u6642\u670d\u7528 CYP3A4 \u8a98\u5c0e\u5291\u548c\/\u6216\u6291\u5236\u5291<\/i>\uff1a\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u6291\u5236\u5291\u548c ORSERDU\u3002\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u8a98\u5c0e\u5291\u548c ORSERDU\u3002<\/p>\n<p><i>\u7279\u5b9a\u4eba\u58eb\u670d\u7528\u9808\u77e5<\/i><\/p>\n<p><i>\u54fa\u4e73\u671f<\/i>\uff1a\u5efa\u8b70\u54fa\u4e73\u5a66\u5973\u670d\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u5207\u52ff\u54fa\u4e73\u3002<br \/><i>\u809d\u529f\u80fd\u53d7\u640d<\/i>\uff1a\u5207\u52ff\u4e88\u56b4\u91cd\u809d\u529f\u80fd\u4e0d\u5168 (Child-Pugh C) \u7684\u60a3\u8005\u670d\u7528 ORSERDU\u3002\u5c0d\u65bc\u4e2d\u5ea6\u809d\u529f\u80fd\u4e0d\u5168\uff08Child-Pugh B\uff09\u7684\u60a3\u8005\uff0c\u61c9\u964d\u4f4e ORSERDU \u7684\u5291\u91cf\u3002<br \/>\u5c1a\u672a\u78ba\u5b9a ORSERDU \u5c0d\u5152\u79d1\u60a3\u8005\u7684\u5b89\u5168\u548c\u6210\u6548\u3002<\/p>\n<p>\u5982\u6b32\u5831\u544a\u61f7\u7591\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff08\u96fb\u8a71\uff1a1-877-332-7961\uff09\u6216\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\uff08\u96fb\u8a71\uff1a1-800-FDA-1088 \u6216\u7db2\u4e0a\u7559\u8a00\uff1a<a href=\"http:\/\/www.fda.gov\/medwatch\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.fda.gov\/medwatch<\/a>\uff09\u3002<\/p>\n<p><b>\u95dc\u65bc Menarini Group<\/b><\/p>\n<p>Menarini Group \u662f\u570b\u969b\u9818\u5148\u7684\u88fd\u85e5\u548c\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u9054 50 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u8d85\u904e 17,000 \u540d\u3002Menarini \u5c08\u6ce8\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u75c5\u5b78\u3001\u816b\u7624\u5b78\u3001\u80ba\u75c5\u5b78\u3001\u80c3\u8178\u75c5\u5b78\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u5b78\u3001\u767c\u708e\u548c\u93ae\u75db\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u904d\u4f48\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.menarini.com&amp;esheet=53558844&amp;newsitemid=20230920907427&amp;lan=en-US&amp;anchor=www.menarini.com&amp;index=5&amp;md5=7682feaaefe280a649c9a9d8a9e54a2c\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">www.menarini.com<\/a>\u3002<\/p>\n<p><b>Stemline Therapeutics Inc. \u7c21\u4ecb<\/b><br \/>Menarini Group \u5168\u8cc7\u5b50\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u662f\u4e00\u9593\u5546\u696d\u968e\u6bb5\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u70ba\u75c5\u4eba\u63d0\u4f9b\u5d84\u65b0\u816b\u7624\u6cbb\u7642\u3002Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316 elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001<i>ESR1<\/i> \u7a81\u8b8a\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u7684\u5df2\u505c\u7d93\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u63a5\u53d7\u6700\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u7642\u6cd5\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u60e1\u5316\u3002Stemline \u4e5f\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269 tagraxofusp-erzs\u3002\u9019\u85e5\u7269\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u72c0\u7d30\u80de\u816b\u7624 (BPDCN)\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002\u6b64\u5916\uff0cStemline \u65bc\u6b50\u6d32\u5546\u696d\u5316 selinexor\uff0c\u9019\u662f\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1\u6291\u5236\u5291\u3002\u8a72\u516c\u53f8\u9084\u5c31\u4e73\u764c\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u9069\u61c9\u75c7\uff0c\u5206\u5225\u5229\u7528 elacestrant \u548c tagraxofusp \u4f5c\u591a\u9805\u6a19\u7c64\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u70ba\u5be6\u9ad4\u764c\u75c7\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u75c5\u4eba\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\uff0c\u64c1\u6709\u8655\u65bc\u4e0d\u540c\u7814\u767c\u968e\u6bb5\u7684\u5ee3\u6cdb\u81e8\u5e8a\u7ba1\u7dda\u3002<\/p>\n<p>[1] Lloyd\u00a0et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. <span class=\"xn-person\">Clin Cancer Res<\/span> (2025).\u00a0<a href=\"https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3033\/768341\/Clinical-and-Genomic-Factors-Associated-with\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3033\/768341\/Clinical-and-Genomic-Factors-Associated-with<\/a><\/p>\n<p>[2] Rugo et al.\u00a0Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. \u00a0Clin Cancer Res, 2025. CCR-25-3040R1.\u00a0<a href=\"https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3040\/768340\/Real-World-Outcomes-of-Elacestrant-in-ER-HER2-ESR1\" target=\"_blank\" rel=\"nofollow\" style=\"color: #0000FF\">https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3040\/768340\/Real-World-Outcomes-of-Elacestrant-in-ER-HER2-ESR1<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u6b64\u5916\uff0celacestrant &#8230;<\/p>\n","protected":false},"author":16,"featured_media":391066,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-391065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u6b64\u5916\uff0celacestrant \u5ee3\u6cdb\u7684\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u6700\u65b0\u9032\u5c55\uff0c\u9032\u4e00\u6b65\u978f\u56fa\u5176\u4f5c\u70ba\u806f\u5408\u6cbb\u7642\u3001\u4ee5\u53ca\u8f49\u79fb\u6027\u548c\u65e9\u671f\u4e73\u764c\u6cbb\u7642\u4e2d\u9aa8\u5e79\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u6f5b\u529b\u3002   \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042025\u5e7412\u670810\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u7684\u85e5\u696d\u53ca\u8a3a\u65b7\u516c\u53f8 Menarini Group\uff08\u4e0b\u7a31\u300cMenarini\u300d\uff09\uff0c\u8207\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u8b8a\u9769\u6027\u816b\u7624\u7642\u6cd5\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u4e0b\u7a31\u300cStemline\u300d\uff09\uff0c\u5ba3\u4f48\u5c07\u516c\u4f48\u7b2c 2 \u671f ELEVATE \u7814\u7a76\u4e2d\u5169\u9805\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u6700\u65b0\u5177\u81e8\u5e8a\u610f\u7fa9\u7684\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7642\u6548\u7d50\u679c\uff0c\u8a72\u7814\u7a76\u91dd\u5c0d\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u3002ELEVATE \u7814\u7a76\u65e8\u5728\u8a55\u4f30\u5168\u53e3\u670d\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u85c9\u4ee5\u514b\u670d ER+\/HER2- mBC \u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6a5f\u5236\uff0c\u5f9e\u800c\u6539\u5584\u60a3\u8005\u7684\u6cbb\u7642\u6210\u6548\u3002\u76f8\u95dc\u6578\u64da\u5c07\u65bc 12 \u6708 9 \u65e5\u81f3 12 \u65e5\u8209\u884c\u7684 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u767c\u8868\u3002 \u300c\u4ee4\u4eba\u9f13\u821e\u7684\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u589e\u5f37\u4e86\u6211\u5011\u5c0d elacestrant \u5728\u806f\u5408\u6cbb\u7642\u4e2d\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642\u9aa8\u5e79\u89d2\u8272\u7684\u4fe1\u5fc3\u3002\u300d\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821\u5065\u5eb7\u79d1\u5b78\u4e2d\u5fc3\u8840\u6db2\u5b78\/\u816b\u7624\u79d1\u91ab\u5b78\u6559\u6388\u517c\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821 MD \u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u4e73\u764c\u9805\u76ee\u8ca0\u8cac\u4eba Virginia Kaklamani \u91ab\u5b78\u535a\u58eb\u8868\u793a\uff0c\u00a0\u300cElacestrant \u8207 everolimus \u6216 abemaciclib \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u7279\u5fb5\uff0c\u8207\u6bcf\u7a2e\u85e5\u7269\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002\u4e26\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u8a0a\u865f\u3002\u300d \u5c07\u65bc SABCS \u767c\u8868\u7684 ELEVATE \u6578\u64da\u986f\u793a\uff0c\u5c0d\u65bc\u66fe\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5f8c\u75c5\u60c5\u60e1\u5316\uff08\u4e0d\u8ad6\u662f\u5426\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\uff09\u7684 ER+\/HER2- mBC \u60a3\u8005\uff0celacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u5747\u986f\u793a\u51fa\u4e00\u81f4\u7684 PFS \u6548\u76ca\uff0c\u4e14\u4e0d\u53d7 ESR1 \u7a81\u8b8a\u72c0\u614b\u5f71\u97ff\u3002\u6700\u65b0\u7d50\u679c\u4ea6\u986f\u793a\uff0c\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8207\u5404\u6a19\u9776\u7642\u6cd5\u52a0\u4e0a\u6a19\u6e96\u8b77\u7406\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u5df2\u77e5\u5b89\u5168\u6027\u4e00\u81f4\u3002 \u7b2c 2 \u671f mPFS\uff08\u6708\uff09\uff0895% \u7f6e\u4fe1\u5340\u9593 \uff09\uff0c\u6db5\u84cb\u6240\u6709\u60a3\u8005\u53ca\u4e9e\u7d44          \u60a3\u8005\u7fa4\u9ad4    Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Everolimus 7.5mg \u6bcf\u65e5\u4e00\u6b21 (n = 50)    Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Abemaciclib 150 mg \u6bcf\u65e5\u5169\u6b21 (n = 60)         \u6240\u6709\u60a3\u8005    8.3    14.3         \u5167\u81df\u8f49\u79fb    7.7    14.3         \u672a\u66fe\u63a5\u53d7 fulvestrant \u6cbb\u7642    8.3    14.8         \u7121\u539f\u767c\u6027\u5167\u5206\u6ccc\u6297\u85e5\u6027    8.3    14.3         ESR1\u7a81\u8b8a    8.7    *         ESR1\u91ce\u751f\u578b    9.0    *         PIK3CA\u7a81\u8b8a    8.3    *         PIK3CA\u91ce\u751f\u578b    9.6    *         *Elacestrant + abemaciclib \u968a\u5217\u4e2d\u7684\u57fa\u56e0\u7d44\u4e9e\u7d44 (ESR1 \/ PIK3CA) \u4e4b PFS \u5c1a\u672a\u6210\u719f (95% CI)\u3002         \u00a0 \u300cElacestrant \u64c1\u6709\u5ee3\u6cdb\u7684\u8b49\u64da\u652f\u6301\uff0c\u6db5\u84cb\u4e86\u6211\u5011\u95dc\u9375 EMERALD \u7814\u7a76\u4e2d\u7684\u55ae\u85e5\u6cbb\u7642\u8a2d\u5b9a\uff08\u73fe\u66f4\u6709\u5169\u4efd\u8fd1\u671f\u767c\u8868\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u6587\u737b\u652f\u6301, \uff09\uff0c\u4ee5\u53ca\u5982 SABCS \u767c\u8868\u6578\u64da\u6240\u5f37\u8abf\uff0c\u5176\u5728\u806f\u5408\u6cbb\u7642\u65b9\u6848\u4e2d\u65e5\u76ca\u589e\u9577\u7684\u6f5b\u529b\u3002\u300dMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff0c\u300c\u6211\u5011\u81f4\u529b\u900f\u904e\u591a\u9805\u91dd\u5c0d\u65e9\u671f\u53ca\u8f49\u79fb\u6027\u4e73\u764c\u7684\u9032\u884c\u4e2d\u8a66\u9a57\uff0c\u5168\u9762\u63a2\u7d22 elacestrant \u7684\u6f5b\u5728\u6548\u76ca\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6 elacestrant \u7684\u66f4\u65b0\u8cc7\u8a0a\u4ea6\u5c07\u65bc SABCS \u767c\u8868\uff0c\u63a2\u8a0e\u5176\u5728\u5404\u985e\u4e73\u764c\u6cbb\u7642\u4e2d\u7684\u6f5b\u529b\uff1a \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u6cbb\u7642 ER+\/HER2- \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\uff1aELEVATE \u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\u7684\u7b2c 2 \u671f\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a1255\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 1:00 \u2013 2:00\u5730\u9ede\uff1aHemisfair 1-2 \u767c\u8868\u6f14\u8b1b\u8005\uff1a Hope S. Rugo \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u55ae\u85e5\u6216\u806f\u5408 triptorelin \u6cbb\u7642 ER+\/HER2- \u65e9\u671f\u4e73\u764c\u7d55\u7d93\u524d\u5973\u6027\uff1aSOLTI-2104-Premi\u00c8Re \u7b2c 2 \u671f\u8a66\u9a57\u7684\u4e3b\u8981\u5206\u6790\u6458\u8981\u7de8\u865f\uff1a1123\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0a\u5348 7:30 \u2013 7:33\u5730\u9ede\uff1a301 ABC\u767c\u8868\u6f14\u8b1b\u8005\uff1aMertixell Bellet \u7c21\u5831\u984c\u76ee\uff1aELEGANT\uff1a\u4e00\u9805\u5728\u5168\u7403\u591a\u4e2d\u5fc3\u9032\u884c\u7684\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\uff0c\u6bd4\u8f03 Elacestrant \u8207\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5728\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c (eBC) \u5973\u6027\u53ca\u7537\u6027\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1276\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAditya Bardia \u7c21\u5831\u984c\u76ee\uff1a ADELA \u7814\u7a76\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u6bd4\u8f03 Elacestrant (ELA) + Everolimus (EVE) \u5c0d\u6bd4 ELA + \u5b89\u6170\u5291 (PBO) \u5728\u66fe\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u53ca CDK4\/6 \u6291\u5236\u5291\u5f8c\u75c5\u60c5\u60e1\u5316\u4e14\u5e36\u6709 ESR1 \u7a81\u8b8a\u816b\u7624\u7684 ER+\/HER2- \u665a\u671f\u4e73\u764c (aBC) \u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1141\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 10 \u65e5\uff08\u661f\u671f\u4e09\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAntonio Llombart-Cussac \u7c21\u5831\u984c\u76ee\uff1aERADICATE\uff1a\u4e00\u9805\u7b2c Ib\/II \u671f\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u806f\u5408 trastuzumab deruxtecan \u6cbb\u7642\u5c0d CDK4\/6 \u6291\u5236\u5291\u53ca\u5167\u5206\u6ccc\u6cbb\u7642\u7522\u751f\u6297\u85e5\u6027\u7684 HR+\/HER2-\u4f4e\u8868\u9054 (low) \u6216 HER2-\u8d85\u4f4e\u8868\u9054 (ultralow) \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002\u6458\u8981\u7de8\u865f\uff1a2119\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1a Henry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aSara L. Sammons \u7c21\u5831\u984c\u76ee\uff1a\u8853\u524d\u63a5\u53d7 Elacestrant \u53ca PULSAR \u81ea\u9069\u61c9\u653e\u5c04\u6cbb\u7642\u7684\u8377\u723e\u8499\u53d7\u9ad4 (HR) \u967d\u6027 HER2 \u9670\u6027\u4e73\u764c\u60a3\u8005\uff1a\u4e00\u9805\u7b2c II \u671f\u7814\u7a76 (HELP \u8a66\u9a57) \u6458\u8981\u7de8\u865f\uff1a1071\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aLuca Visani \u95dc\u65bc Elacestrant Clinical Development Program \u6b64\u5916\uff0c\u8a72\u516c\u53f8\u4e5f\u8d0a\u52a9\u591a\u9805\u8f49\u79fb\u6027\u4e73\u764c\u7684\u81e8\u5e8a\u8a66\u9a57\uff0c\u63a2\u8a0e elacestrant \u55ae\u7368\u6216\u7d50\u5408\u5176\u4ed6\u7642\u6cd5\u7684\u6cbb\u7642\u3002ELEVATE (NCT05563220) \u662f\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 alpelisib\u3001everolimus\u3001capivasertib\u3001palbociclib\u3001ribociclib \u6216 abemaciclib \u7684\u5b89\u5168\u8207\u7642\u6548\u3002ELECTRA (NCT05386108) \u662f\u7b2c 1b\/2 \u671f\u3001\u958b\u653e\u6a19\u7c64\u517c\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 abemaciclib \u670d\u7528\uff0c\u5c0d ER+ \u548c HER2- \u4e73\u764c\u60a3\u8005\u7684\u6548\u679c\u3002\u7b2c 2 \u968e\u6bb5\u5247\u8a55\u4f30\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6cbb\u7642\u65b9\u6848\u3002ELCIN (NCT05596409) \u662f\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u5c0d ER+ \u548c HER2- \u665a\u671f\/\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\u3002\u9019\u4e9b\u60a3\u8005\u66fe\u63a5\u53d7\u4e00\u81f3\u5169\u7a2e\u8377\u723e\u8499\u7642\u6cd5\uff0c\u4f46\u5728\u8f49\u79fb\u6027\u60c5\u6cc1\u4e2d\uff0c\u672a\u66fe\u670d\u7528 CDK4\/6 \u6291\u5236\u5291\u3002ADELA (NCT06382948) \u662f\u7b2c 3 \u671f\u3001\u96a8\u6a5f\u517c\u96d9\u76f2\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 everolimus \u6cbb\u7642 ER+ \u548c HER2- mBC \u53ca ESR1-mut \u816b\u7624\u60a3\u8005\u7684\u7642\u6548\u3002Elacestrant \u4e5f\u65bc\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\uff0c\u70ba\u8f49\u79fb\u6027\u4e73\u764c\u548c\u65e9\u671f\u75be\u75c5\u9032\u884c\u8a55\u4f30\u3002 \u95dc\u65bc ORSERDU (elacestrant)\u5728\u7f8e\u570b\u6838\u51c6\u7684\u9069\u61c9\u75c7\uff1aORSERDU (elacestrant) \u662f 345 \u6beb\u514b\u7247\u5291\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u6216\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ESR1) \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u517c\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u65bc\u63a5\u53d7\u81f3\u5c11\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u9032\u5c55\u3002 \u5982\u6b32\u4e86\u89e3\u7f8e\u570b\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u6599\uff0c\u8acb\u700f\u89bd www.orserdu.com\u3002 \u91cd\u8981\u5b89\u5168\u8cc7\u8a0a\u8b66\u544a\u548c\u6ce8\u610f\u4e8b\u9805 \u9ad8\u8102\u8840\u75c7\uff1a\u670d\u7528 ORSERDU \u7684\u60a3\u8005\u4e2d\uff0c\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 30% \u548c 27%\u3002\u7b2c 3 \u7d1a\u548c\u7b2c 4 \u7d1a\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 0.9% \u548c 2.2%\u3002\u958b\u59cb\u670d\u7528 ORSERDU \u524d\u548c\u670d\u7528\u671f\u9593\uff0c\u5b9a\u671f\u76e3\u6e2c\u8840\u8102\u72c0\u6cc1\u3002 \u80da\u80ce-\u80ce\u5152\u6bd2\u6027\uff1a\u6839\u64da\u52d5\u7269\u5be6\u9a57\u7d50\u679c\u53ca\u7576\u4e2d\u4f5c\u7528\u6a5f\u5236\uff0c\u5b55\u5a66\u670d\u7528 ORSERDU\uff0c\u53ef\u80fd\u5c0d\u80ce\u5152\u9020\u6210\u50b7\u5bb3\u3002\u8acb\u544a\u77e5\u5b55\u5a66\u548c\u80b2\u9f61\u5973\u6027\uff0c\u80ce\u5152\u53ef\u80fd\u9762\u5c0d\u7684\u98a8\u96aa\u3002\u5efa\u8b70\u80b2\u9f61\u5973\u6027\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u548c\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002\u5efa\u8b70\u6709\u751f\u80b2\u80fd\u529b\u5973\u6027\u4f34\u4fb6\u7684\u7537\u6027\u60a3\u8005\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002 \u4e0d\u826f\u53cd\u61c9 12% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\uff0c\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\u3002\u5728\u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0c\u8d85\u904e 1% \u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u808c\u8089\u9aa8\u9abc\u75bc\u75db (1.7%) \u548c\u5641\u5fc3 (1.3%)\u30021.7% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u51fa\u73fe\u81f4\u547d\u7684\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u5fc3\u81df\u9a5f\u505c\u3001\u6557\u8840\u6027\u4f11\u514b\u3001\u61a9\u5ba4\u708e\u548c\u539f\u56e0\u4e0d\u660e\u7684\u60c5\u6cc1\uff08\u5404\u4e00\u4f8b\uff09\u3002ORSERDU \u6700\u5e38\u898b\u7684\u4e0d\u826f\u53cd\u61c9 (&gt; 10%)\uff0c\u5305\u62ec\u5be6\u9a57\u5ba4\u7570\u5e38\uff0c\u662f\u808c\u8089\u9aa8\u9abc\u75bc\u75db (41%)\u3001\u5641\u5fc3 (35%)\u3001\u81bd\u56fa\u9187\u5347\u9ad8 (30%)\u3001AST \u589e\u52a0 (29%)\u3001\u7518\u6cb9\u4e09\u916f\u589e\u52a0 (27%)\u3001\u75b2\u52de (26%)\u3001\u8840\u7d05\u86cb\u767d\u4e0b\u964d (26%)\u3001\u5614\u5410 (19%)\u3001ALT \u589e\u9ad8 (17%)\u3001\u9209\u964d\u4f4e (16%)\u3001\u808c\u9178\u589e\u52a0 (16%)\u3001\u98df\u617e\u4e0b\u964d (15%)\u3001\u8179\u7009 (13%)\u3001\u982d\u75db (12%)\u3001\u4fbf\u79d8 (12%)\u3001\u8179\u75db (11%)\u3001\u6f6e\u71b1 (11%) \u548c\u6d88\u5316\u4e0d\u826f (10%)\u3002 \u85e5\u7269\u4ea4\u4e92\u53cd\u61c9 \u540c\u6642\u670d\u7528 CYP3A4 \u8a98\u5c0e\u5291\u548c\/\u6216\u6291\u5236\u5291\uff1a\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u6291\u5236\u5291\u548c ORSERDU\u3002\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u8a98\u5c0e\u5291\u548c ORSERDU\u3002 \u7279\u5b9a\u4eba\u58eb\u670d\u7528\u9808\u77e5 \u54fa\u4e73\u671f\uff1a\u5efa\u8b70\u54fa\u4e73\u5a66\u5973\u670d\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u5207\u52ff\u54fa\u4e73\u3002\u809d\u529f\u80fd\u53d7\u640d\uff1a\u5207\u52ff\u4e88\u56b4\u91cd\u809d\u529f\u80fd\u4e0d\u5168 (Child-Pugh C) \u7684\u60a3\u8005\u670d\u7528 ORSERDU\u3002\u5c0d\u65bc\u4e2d\u5ea6\u809d\u529f\u80fd\u4e0d\u5168\uff08Child-Pugh B\uff09\u7684\u60a3\u8005\uff0c\u61c9\u964d\u4f4e ORSERDU \u7684\u5291\u91cf\u3002\u5c1a\u672a\u78ba\u5b9a ORSERDU \u5c0d\u5152\u79d1\u60a3\u8005\u7684\u5b89\u5168\u548c\u6210\u6548\u3002 \u5982\u6b32\u5831\u544a\u61f7\u7591\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff08\u96fb\u8a71\uff1a1-877-332-7961\uff09\u6216\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\uff08\u96fb\u8a71\uff1a1-800-FDA-1088 \u6216\u7db2\u4e0a\u7559\u8a00\uff1awww.fda.gov\/medwatch\uff09\u3002 \u95dc\u65bc Menarini Group Menarini Group \u662f\u570b\u969b\u9818\u5148\u7684\u88fd\u85e5\u548c\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u9054 50 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u8d85\u904e 17,000 \u540d\u3002Menarini \u5c08\u6ce8\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u75c5\u5b78\u3001\u816b\u7624\u5b78\u3001\u80ba\u75c5\u5b78\u3001\u80c3\u8178\u75c5\u5b78\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u5b78\u3001\u767c\u708e\u548c\u93ae\u75db\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u904d\u4f48\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 Stemline Therapeutics Inc. \u7c21\u4ecbMenarini Group \u5168\u8cc7\u5b50\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u662f\u4e00\u9593\u5546\u696d\u968e\u6bb5\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u70ba\u75c5\u4eba\u63d0\u4f9b\u5d84\u65b0\u816b\u7624\u6cbb\u7642\u3002Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316 elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u7684\u5df2\u505c\u7d93\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u63a5\u53d7\u6700\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u7642\u6cd5\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u60e1\u5316\u3002Stemline \u4e5f\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269 tagraxofusp-erzs\u3002\u9019\u85e5\u7269\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u72c0\u7d30\u80de\u816b\u7624 (BPDCN)\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002\u6b64\u5916\uff0cStemline \u65bc\u6b50\u6d32\u5546\u696d\u5316 selinexor\uff0c\u9019\u662f\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1\u6291\u5236\u5291\u3002\u8a72\u516c\u53f8\u9084\u5c31\u4e73\u764c\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u9069\u61c9\u75c7\uff0c\u5206\u5225\u5229\u7528 elacestrant \u548c tagraxofusp \u4f5c\u591a\u9805\u6a19\u7c64\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u70ba\u5be6\u9ad4\u764c\u75c7\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u75c5\u4eba\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\uff0c\u64c1\u6709\u8655\u65bc\u4e0d\u540c\u7814\u767c\u968e\u6bb5\u7684\u5ee3\u6cdb\u81e8\u5e8a\u7ba1\u7dda\u3002  Lloyd\u00a0et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3033\/768341\/Clinical-and-Genomic-Factors-Associated-with  Rugo et al.\u00a0Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. \u00a0Clin Cancer Res, 2025. CCR-25-3040R1.\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3040\/768340\/Real-World-Outcomes-of-Elacestrant-in-ER-HER2-ESR1\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=391065\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u6b64\u5916\uff0celacestrant \u5ee3\u6cdb\u7684\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u6700\u65b0\u9032\u5c55\uff0c\u9032\u4e00\u6b65\u978f\u56fa\u5176\u4f5c\u70ba\u806f\u5408\u6cbb\u7642\u3001\u4ee5\u53ca\u8f49\u79fb\u6027\u548c\u65e9\u671f\u4e73\u764c\u6cbb\u7642\u4e2d\u9aa8\u5e79\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u6f5b\u529b\u3002   \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042025\u5e7412\u670810\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u7684\u85e5\u696d\u53ca\u8a3a\u65b7\u516c\u53f8 Menarini Group\uff08\u4e0b\u7a31\u300cMenarini\u300d\uff09\uff0c\u8207\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u8b8a\u9769\u6027\u816b\u7624\u7642\u6cd5\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u4e0b\u7a31\u300cStemline\u300d\uff09\uff0c\u5ba3\u4f48\u5c07\u516c\u4f48\u7b2c 2 \u671f ELEVATE \u7814\u7a76\u4e2d\u5169\u9805\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u6700\u65b0\u5177\u81e8\u5e8a\u610f\u7fa9\u7684\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7642\u6548\u7d50\u679c\uff0c\u8a72\u7814\u7a76\u91dd\u5c0d\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u3002ELEVATE \u7814\u7a76\u65e8\u5728\u8a55\u4f30\u5168\u53e3\u670d\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u85c9\u4ee5\u514b\u670d ER+\/HER2- mBC \u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6a5f\u5236\uff0c\u5f9e\u800c\u6539\u5584\u60a3\u8005\u7684\u6cbb\u7642\u6210\u6548\u3002\u76f8\u95dc\u6578\u64da\u5c07\u65bc 12 \u6708 9 \u65e5\u81f3 12 \u65e5\u8209\u884c\u7684 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u767c\u8868\u3002 \u300c\u4ee4\u4eba\u9f13\u821e\u7684\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u589e\u5f37\u4e86\u6211\u5011\u5c0d elacestrant \u5728\u806f\u5408\u6cbb\u7642\u4e2d\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642\u9aa8\u5e79\u89d2\u8272\u7684\u4fe1\u5fc3\u3002\u300d\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821\u5065\u5eb7\u79d1\u5b78\u4e2d\u5fc3\u8840\u6db2\u5b78\/\u816b\u7624\u79d1\u91ab\u5b78\u6559\u6388\u517c\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821 MD \u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u4e73\u764c\u9805\u76ee\u8ca0\u8cac\u4eba Virginia Kaklamani \u91ab\u5b78\u535a\u58eb\u8868\u793a\uff0c\u00a0\u300cElacestrant \u8207 everolimus \u6216 abemaciclib \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u7279\u5fb5\uff0c\u8207\u6bcf\u7a2e\u85e5\u7269\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002\u4e26\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u8a0a\u865f\u3002\u300d \u5c07\u65bc SABCS \u767c\u8868\u7684 ELEVATE \u6578\u64da\u986f\u793a\uff0c\u5c0d\u65bc\u66fe\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5f8c\u75c5\u60c5\u60e1\u5316\uff08\u4e0d\u8ad6\u662f\u5426\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\uff09\u7684 ER+\/HER2- mBC \u60a3\u8005\uff0celacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u5747\u986f\u793a\u51fa\u4e00\u81f4\u7684 PFS \u6548\u76ca\uff0c\u4e14\u4e0d\u53d7 ESR1 \u7a81\u8b8a\u72c0\u614b\u5f71\u97ff\u3002\u6700\u65b0\u7d50\u679c\u4ea6\u986f\u793a\uff0c\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8207\u5404\u6a19\u9776\u7642\u6cd5\u52a0\u4e0a\u6a19\u6e96\u8b77\u7406\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u5df2\u77e5\u5b89\u5168\u6027\u4e00\u81f4\u3002 \u7b2c 2 \u671f mPFS\uff08\u6708\uff09\uff0895% \u7f6e\u4fe1\u5340\u9593 \uff09\uff0c\u6db5\u84cb\u6240\u6709\u60a3\u8005\u53ca\u4e9e\u7d44          \u60a3\u8005\u7fa4\u9ad4    Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Everolimus 7.5mg \u6bcf\u65e5\u4e00\u6b21 (n = 50)    Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Abemaciclib 150 mg \u6bcf\u65e5\u5169\u6b21 (n = 60)         \u6240\u6709\u60a3\u8005    8.3    14.3         \u5167\u81df\u8f49\u79fb    7.7    14.3         \u672a\u66fe\u63a5\u53d7 fulvestrant \u6cbb\u7642    8.3    14.8         \u7121\u539f\u767c\u6027\u5167\u5206\u6ccc\u6297\u85e5\u6027    8.3    14.3         ESR1\u7a81\u8b8a    8.7    *         ESR1\u91ce\u751f\u578b    9.0    *         PIK3CA\u7a81\u8b8a    8.3    *         PIK3CA\u91ce\u751f\u578b    9.6    *         *Elacestrant + abemaciclib \u968a\u5217\u4e2d\u7684\u57fa\u56e0\u7d44\u4e9e\u7d44 (ESR1 \/ PIK3CA) \u4e4b PFS \u5c1a\u672a\u6210\u719f (95% CI)\u3002         \u00a0 \u300cElacestrant \u64c1\u6709\u5ee3\u6cdb\u7684\u8b49\u64da\u652f\u6301\uff0c\u6db5\u84cb\u4e86\u6211\u5011\u95dc\u9375 EMERALD \u7814\u7a76\u4e2d\u7684\u55ae\u85e5\u6cbb\u7642\u8a2d\u5b9a\uff08\u73fe\u66f4\u6709\u5169\u4efd\u8fd1\u671f\u767c\u8868\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u6587\u737b\u652f\u6301, \uff09\uff0c\u4ee5\u53ca\u5982 SABCS \u767c\u8868\u6578\u64da\u6240\u5f37\u8abf\uff0c\u5176\u5728\u806f\u5408\u6cbb\u7642\u65b9\u6848\u4e2d\u65e5\u76ca\u589e\u9577\u7684\u6f5b\u529b\u3002\u300dMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff0c\u300c\u6211\u5011\u81f4\u529b\u900f\u904e\u591a\u9805\u91dd\u5c0d\u65e9\u671f\u53ca\u8f49\u79fb\u6027\u4e73\u764c\u7684\u9032\u884c\u4e2d\u8a66\u9a57\uff0c\u5168\u9762\u63a2\u7d22 elacestrant \u7684\u6f5b\u5728\u6548\u76ca\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6 elacestrant \u7684\u66f4\u65b0\u8cc7\u8a0a\u4ea6\u5c07\u65bc SABCS \u767c\u8868\uff0c\u63a2\u8a0e\u5176\u5728\u5404\u985e\u4e73\u764c\u6cbb\u7642\u4e2d\u7684\u6f5b\u529b\uff1a \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u6cbb\u7642 ER+\/HER2- \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\uff1aELEVATE \u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\u7684\u7b2c 2 \u671f\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a1255\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 1:00 \u2013 2:00\u5730\u9ede\uff1aHemisfair 1-2 \u767c\u8868\u6f14\u8b1b\u8005\uff1a Hope S. Rugo \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u55ae\u85e5\u6216\u806f\u5408 triptorelin \u6cbb\u7642 ER+\/HER2- \u65e9\u671f\u4e73\u764c\u7d55\u7d93\u524d\u5973\u6027\uff1aSOLTI-2104-Premi\u00c8Re \u7b2c 2 \u671f\u8a66\u9a57\u7684\u4e3b\u8981\u5206\u6790\u6458\u8981\u7de8\u865f\uff1a1123\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0a\u5348 7:30 \u2013 7:33\u5730\u9ede\uff1a301 ABC\u767c\u8868\u6f14\u8b1b\u8005\uff1aMertixell Bellet \u7c21\u5831\u984c\u76ee\uff1aELEGANT\uff1a\u4e00\u9805\u5728\u5168\u7403\u591a\u4e2d\u5fc3\u9032\u884c\u7684\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\uff0c\u6bd4\u8f03 Elacestrant \u8207\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5728\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c (eBC) \u5973\u6027\u53ca\u7537\u6027\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1276\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAditya Bardia \u7c21\u5831\u984c\u76ee\uff1a ADELA \u7814\u7a76\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u6bd4\u8f03 Elacestrant (ELA) + Everolimus (EVE) \u5c0d\u6bd4 ELA + \u5b89\u6170\u5291 (PBO) \u5728\u66fe\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u53ca CDK4\/6 \u6291\u5236\u5291\u5f8c\u75c5\u60c5\u60e1\u5316\u4e14\u5e36\u6709 ESR1 \u7a81\u8b8a\u816b\u7624\u7684 ER+\/HER2- \u665a\u671f\u4e73\u764c (aBC) \u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1141\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 10 \u65e5\uff08\u661f\u671f\u4e09\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAntonio Llombart-Cussac \u7c21\u5831\u984c\u76ee\uff1aERADICATE\uff1a\u4e00\u9805\u7b2c Ib\/II \u671f\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u806f\u5408 trastuzumab deruxtecan \u6cbb\u7642\u5c0d CDK4\/6 \u6291\u5236\u5291\u53ca\u5167\u5206\u6ccc\u6cbb\u7642\u7522\u751f\u6297\u85e5\u6027\u7684 HR+\/HER2-\u4f4e\u8868\u9054 (low) \u6216 HER2-\u8d85\u4f4e\u8868\u9054 (ultralow) \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002\u6458\u8981\u7de8\u865f\uff1a2119\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1a Henry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aSara L. Sammons \u7c21\u5831\u984c\u76ee\uff1a\u8853\u524d\u63a5\u53d7 Elacestrant \u53ca PULSAR \u81ea\u9069\u61c9\u653e\u5c04\u6cbb\u7642\u7684\u8377\u723e\u8499\u53d7\u9ad4 (HR) \u967d\u6027 HER2 \u9670\u6027\u4e73\u764c\u60a3\u8005\uff1a\u4e00\u9805\u7b2c II \u671f\u7814\u7a76 (HELP \u8a66\u9a57) \u6458\u8981\u7de8\u865f\uff1a1071\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aLuca Visani \u95dc\u65bc Elacestrant Clinical Development Program \u6b64\u5916\uff0c\u8a72\u516c\u53f8\u4e5f\u8d0a\u52a9\u591a\u9805\u8f49\u79fb\u6027\u4e73\u764c\u7684\u81e8\u5e8a\u8a66\u9a57\uff0c\u63a2\u8a0e elacestrant \u55ae\u7368\u6216\u7d50\u5408\u5176\u4ed6\u7642\u6cd5\u7684\u6cbb\u7642\u3002ELEVATE (NCT05563220) \u662f\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 alpelisib\u3001everolimus\u3001capivasertib\u3001palbociclib\u3001ribociclib \u6216 abemaciclib \u7684\u5b89\u5168\u8207\u7642\u6548\u3002ELECTRA (NCT05386108) \u662f\u7b2c 1b\/2 \u671f\u3001\u958b\u653e\u6a19\u7c64\u517c\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 abemaciclib \u670d\u7528\uff0c\u5c0d ER+ \u548c HER2- \u4e73\u764c\u60a3\u8005\u7684\u6548\u679c\u3002\u7b2c 2 \u968e\u6bb5\u5247\u8a55\u4f30\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6cbb\u7642\u65b9\u6848\u3002ELCIN (NCT05596409) \u662f\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u5c0d ER+ \u548c HER2- \u665a\u671f\/\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\u3002\u9019\u4e9b\u60a3\u8005\u66fe\u63a5\u53d7\u4e00\u81f3\u5169\u7a2e\u8377\u723e\u8499\u7642\u6cd5\uff0c\u4f46\u5728\u8f49\u79fb\u6027\u60c5\u6cc1\u4e2d\uff0c\u672a\u66fe\u670d\u7528 CDK4\/6 \u6291\u5236\u5291\u3002ADELA (NCT06382948) \u662f\u7b2c 3 \u671f\u3001\u96a8\u6a5f\u517c\u96d9\u76f2\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 everolimus \u6cbb\u7642 ER+ \u548c HER2- mBC \u53ca ESR1-mut \u816b\u7624\u60a3\u8005\u7684\u7642\u6548\u3002Elacestrant \u4e5f\u65bc\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\uff0c\u70ba\u8f49\u79fb\u6027\u4e73\u764c\u548c\u65e9\u671f\u75be\u75c5\u9032\u884c\u8a55\u4f30\u3002 \u95dc\u65bc ORSERDU (elacestrant)\u5728\u7f8e\u570b\u6838\u51c6\u7684\u9069\u61c9\u75c7\uff1aORSERDU (elacestrant) \u662f 345 \u6beb\u514b\u7247\u5291\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u6216\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ESR1) \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u517c\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u65bc\u63a5\u53d7\u81f3\u5c11\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u9032\u5c55\u3002 \u5982\u6b32\u4e86\u89e3\u7f8e\u570b\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u6599\uff0c\u8acb\u700f\u89bd www.orserdu.com\u3002 \u91cd\u8981\u5b89\u5168\u8cc7\u8a0a\u8b66\u544a\u548c\u6ce8\u610f\u4e8b\u9805 \u9ad8\u8102\u8840\u75c7\uff1a\u670d\u7528 ORSERDU \u7684\u60a3\u8005\u4e2d\uff0c\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 30% \u548c 27%\u3002\u7b2c 3 \u7d1a\u548c\u7b2c 4 \u7d1a\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 0.9% \u548c 2.2%\u3002\u958b\u59cb\u670d\u7528 ORSERDU \u524d\u548c\u670d\u7528\u671f\u9593\uff0c\u5b9a\u671f\u76e3\u6e2c\u8840\u8102\u72c0\u6cc1\u3002 \u80da\u80ce-\u80ce\u5152\u6bd2\u6027\uff1a\u6839\u64da\u52d5\u7269\u5be6\u9a57\u7d50\u679c\u53ca\u7576\u4e2d\u4f5c\u7528\u6a5f\u5236\uff0c\u5b55\u5a66\u670d\u7528 ORSERDU\uff0c\u53ef\u80fd\u5c0d\u80ce\u5152\u9020\u6210\u50b7\u5bb3\u3002\u8acb\u544a\u77e5\u5b55\u5a66\u548c\u80b2\u9f61\u5973\u6027\uff0c\u80ce\u5152\u53ef\u80fd\u9762\u5c0d\u7684\u98a8\u96aa\u3002\u5efa\u8b70\u80b2\u9f61\u5973\u6027\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u548c\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002\u5efa\u8b70\u6709\u751f\u80b2\u80fd\u529b\u5973\u6027\u4f34\u4fb6\u7684\u7537\u6027\u60a3\u8005\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002 \u4e0d\u826f\u53cd\u61c9 12% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\uff0c\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\u3002\u5728\u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0c\u8d85\u904e 1% \u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u808c\u8089\u9aa8\u9abc\u75bc\u75db (1.7%) \u548c\u5641\u5fc3 (1.3%)\u30021.7% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u51fa\u73fe\u81f4\u547d\u7684\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u5fc3\u81df\u9a5f\u505c\u3001\u6557\u8840\u6027\u4f11\u514b\u3001\u61a9\u5ba4\u708e\u548c\u539f\u56e0\u4e0d\u660e\u7684\u60c5\u6cc1\uff08\u5404\u4e00\u4f8b\uff09\u3002ORSERDU \u6700\u5e38\u898b\u7684\u4e0d\u826f\u53cd\u61c9 (&gt; 10%)\uff0c\u5305\u62ec\u5be6\u9a57\u5ba4\u7570\u5e38\uff0c\u662f\u808c\u8089\u9aa8\u9abc\u75bc\u75db (41%)\u3001\u5641\u5fc3 (35%)\u3001\u81bd\u56fa\u9187\u5347\u9ad8 (30%)\u3001AST \u589e\u52a0 (29%)\u3001\u7518\u6cb9\u4e09\u916f\u589e\u52a0 (27%)\u3001\u75b2\u52de (26%)\u3001\u8840\u7d05\u86cb\u767d\u4e0b\u964d (26%)\u3001\u5614\u5410 (19%)\u3001ALT \u589e\u9ad8 (17%)\u3001\u9209\u964d\u4f4e (16%)\u3001\u808c\u9178\u589e\u52a0 (16%)\u3001\u98df\u617e\u4e0b\u964d (15%)\u3001\u8179\u7009 (13%)\u3001\u982d\u75db (12%)\u3001\u4fbf\u79d8 (12%)\u3001\u8179\u75db (11%)\u3001\u6f6e\u71b1 (11%) \u548c\u6d88\u5316\u4e0d\u826f (10%)\u3002 \u85e5\u7269\u4ea4\u4e92\u53cd\u61c9 \u540c\u6642\u670d\u7528 CYP3A4 \u8a98\u5c0e\u5291\u548c\/\u6216\u6291\u5236\u5291\uff1a\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u6291\u5236\u5291\u548c ORSERDU\u3002\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u8a98\u5c0e\u5291\u548c ORSERDU\u3002 \u7279\u5b9a\u4eba\u58eb\u670d\u7528\u9808\u77e5 \u54fa\u4e73\u671f\uff1a\u5efa\u8b70\u54fa\u4e73\u5a66\u5973\u670d\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u5207\u52ff\u54fa\u4e73\u3002\u809d\u529f\u80fd\u53d7\u640d\uff1a\u5207\u52ff\u4e88\u56b4\u91cd\u809d\u529f\u80fd\u4e0d\u5168 (Child-Pugh C) \u7684\u60a3\u8005\u670d\u7528 ORSERDU\u3002\u5c0d\u65bc\u4e2d\u5ea6\u809d\u529f\u80fd\u4e0d\u5168\uff08Child-Pugh B\uff09\u7684\u60a3\u8005\uff0c\u61c9\u964d\u4f4e ORSERDU \u7684\u5291\u91cf\u3002\u5c1a\u672a\u78ba\u5b9a ORSERDU \u5c0d\u5152\u79d1\u60a3\u8005\u7684\u5b89\u5168\u548c\u6210\u6548\u3002 \u5982\u6b32\u5831\u544a\u61f7\u7591\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff08\u96fb\u8a71\uff1a1-877-332-7961\uff09\u6216\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\uff08\u96fb\u8a71\uff1a1-800-FDA-1088 \u6216\u7db2\u4e0a\u7559\u8a00\uff1awww.fda.gov\/medwatch\uff09\u3002 \u95dc\u65bc Menarini Group Menarini Group \u662f\u570b\u969b\u9818\u5148\u7684\u88fd\u85e5\u548c\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u9054 50 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u8d85\u904e 17,000 \u540d\u3002Menarini \u5c08\u6ce8\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u75c5\u5b78\u3001\u816b\u7624\u5b78\u3001\u80ba\u75c5\u5b78\u3001\u80c3\u8178\u75c5\u5b78\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u5b78\u3001\u767c\u708e\u548c\u93ae\u75db\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u904d\u4f48\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 Stemline Therapeutics Inc. \u7c21\u4ecbMenarini Group \u5168\u8cc7\u5b50\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u662f\u4e00\u9593\u5546\u696d\u968e\u6bb5\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u70ba\u75c5\u4eba\u63d0\u4f9b\u5d84\u65b0\u816b\u7624\u6cbb\u7642\u3002Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316 elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u7684\u5df2\u505c\u7d93\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u63a5\u53d7\u6700\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u7642\u6cd5\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u60e1\u5316\u3002Stemline \u4e5f\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269 tagraxofusp-erzs\u3002\u9019\u85e5\u7269\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u72c0\u7d30\u80de\u816b\u7624 (BPDCN)\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002\u6b64\u5916\uff0cStemline \u65bc\u6b50\u6d32\u5546\u696d\u5316 selinexor\uff0c\u9019\u662f\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1\u6291\u5236\u5291\u3002\u8a72\u516c\u53f8\u9084\u5c31\u4e73\u764c\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u9069\u61c9\u75c7\uff0c\u5206\u5225\u5229\u7528 elacestrant \u548c tagraxofusp \u4f5c\u591a\u9805\u6a19\u7c64\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u70ba\u5be6\u9ad4\u764c\u75c7\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u75c5\u4eba\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\uff0c\u64c1\u6709\u8655\u65bc\u4e0d\u540c\u7814\u767c\u968e\u6bb5\u7684\u5ee3\u6cdb\u81e8\u5e8a\u7ba1\u7dda\u3002  Lloyd\u00a0et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3033\/768341\/Clinical-and-Genomic-Factors-Associated-with  Rugo et al.\u00a0Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. \u00a0Clin Cancer Res, 2025. CCR-25-3040R1.\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3040\/768340\/Real-World-Outcomes-of-Elacestrant-in-ER-HER2-ESR1\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=391065\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-09T19:24:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1706\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da\",\"datePublished\":\"2025-12-09T19:24:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065\"},\"wordCount\":374,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065\",\"name\":\"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg\",\"datePublished\":\"2025-12-09T19:24:00+00:00\",\"description\":\"\u6b64\u5916\uff0celacestrant \u5ee3\u6cdb\u7684\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u6700\u65b0\u9032\u5c55\uff0c\u9032\u4e00\u6b65\u978f\u56fa\u5176\u4f5c\u70ba\u806f\u5408\u6cbb\u7642\u3001\u4ee5\u53ca\u8f49\u79fb\u6027\u548c\u65e9\u671f\u4e73\u764c\u6cbb\u7642\u4e2d\u9aa8\u5e79\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u6f5b\u529b\u3002 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042025\u5e7412\u670810\u65e5 \\\/\u7f8e\u901a\u793e\\\/ -- \u570b\u969b\u9818\u5148\u7684\u85e5\u696d\u53ca\u8a3a\u65b7\u516c\u53f8 Menarini Group\uff08\u4e0b\u7a31\u300cMenarini\u300d\uff09\uff0c\u8207\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u8b8a\u9769\u6027\u816b\u7624\u7642\u6cd5\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u4e0b\u7a31\u300cStemline\u300d\uff09\uff0c\u5ba3\u4f48\u5c07\u516c\u4f48\u7b2c 2 \u671f ELEVATE \u7814\u7a76\u4e2d\u5169\u9805\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u6700\u65b0\u5177\u81e8\u5e8a\u610f\u7fa9\u7684\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7642\u6548\u7d50\u679c\uff0c\u8a72\u7814\u7a76\u91dd\u5c0d\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u3002ELEVATE \u7814\u7a76\u65e8\u5728\u8a55\u4f30\u5168\u53e3\u670d\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u85c9\u4ee5\u514b\u670d ER+\\\/HER2- mBC \u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6a5f\u5236\uff0c\u5f9e\u800c\u6539\u5584\u60a3\u8005\u7684\u6cbb\u7642\u6210\u6548\u3002\u76f8\u95dc\u6578\u64da\u5c07\u65bc 12 \u6708 9 \u65e5\u81f3 12 \u65e5\u8209\u884c\u7684 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u767c\u8868\u3002 \u300c\u4ee4\u4eba\u9f13\u821e\u7684\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u589e\u5f37\u4e86\u6211\u5011\u5c0d elacestrant \u5728\u806f\u5408\u6cbb\u7642\u4e2d\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642\u9aa8\u5e79\u89d2\u8272\u7684\u4fe1\u5fc3\u3002\u300d\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821\u5065\u5eb7\u79d1\u5b78\u4e2d\u5fc3\u8840\u6db2\u5b78\\\/\u816b\u7624\u79d1\u91ab\u5b78\u6559\u6388\u517c\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821 MD \u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u4e73\u764c\u9805\u76ee\u8ca0\u8cac\u4eba Virginia Kaklamani \u91ab\u5b78\u535a\u58eb\u8868\u793a\uff0c\u00a0\u300cElacestrant \u8207 everolimus \u6216 abemaciclib \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u7279\u5fb5\uff0c\u8207\u6bcf\u7a2e\u85e5\u7269\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002\u4e26\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u8a0a\u865f\u3002\u300d \u5c07\u65bc SABCS \u767c\u8868\u7684 ELEVATE \u6578\u64da\u986f\u793a\uff0c\u5c0d\u65bc\u66fe\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5f8c\u75c5\u60c5\u60e1\u5316\uff08\u4e0d\u8ad6\u662f\u5426\u66fe\u4f7f\u7528 CDK4\\\/6 \u6291\u5236\u5291\uff09\u7684 ER+\\\/HER2- mBC \u60a3\u8005\uff0celacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u5747\u986f\u793a\u51fa\u4e00\u81f4\u7684 PFS \u6548\u76ca\uff0c\u4e14\u4e0d\u53d7 ESR1 \u7a81\u8b8a\u72c0\u614b\u5f71\u97ff\u3002\u6700\u65b0\u7d50\u679c\u4ea6\u986f\u793a\uff0c\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8207\u5404\u6a19\u9776\u7642\u6cd5\u52a0\u4e0a\u6a19\u6e96\u8b77\u7406\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u5df2\u77e5\u5b89\u5168\u6027\u4e00\u81f4\u3002 \u7b2c 2 \u671f mPFS\uff08\u6708\uff09\uff0895% \u7f6e\u4fe1\u5340\u9593 \uff09\uff0c\u6db5\u84cb\u6240\u6709\u60a3\u8005\u53ca\u4e9e\u7d44 \u60a3\u8005\u7fa4\u9ad4 Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Everolimus 7.5mg \u6bcf\u65e5\u4e00\u6b21 (n = 50) Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Abemaciclib 150 mg \u6bcf\u65e5\u5169\u6b21 (n = 60) \u6240\u6709\u60a3\u8005 8.3 14.3 \u5167\u81df\u8f49\u79fb 7.7 14.3 \u672a\u66fe\u63a5\u53d7 fulvestrant \u6cbb\u7642 8.3 14.8 \u7121\u539f\u767c\u6027\u5167\u5206\u6ccc\u6297\u85e5\u6027 8.3 14.3 ESR1\u7a81\u8b8a 8.7 * ESR1\u91ce\u751f\u578b 9.0 * PIK3CA\u7a81\u8b8a 8.3 * PIK3CA\u91ce\u751f\u578b 9.6 * *Elacestrant + abemaciclib \u968a\u5217\u4e2d\u7684\u57fa\u56e0\u7d44\u4e9e\u7d44 (ESR1 \\\/ PIK3CA) \u4e4b PFS \u5c1a\u672a\u6210\u719f (95% CI)\u3002 \u00a0 \u300cElacestrant \u64c1\u6709\u5ee3\u6cdb\u7684\u8b49\u64da\u652f\u6301\uff0c\u6db5\u84cb\u4e86\u6211\u5011\u95dc\u9375 EMERALD \u7814\u7a76\u4e2d\u7684\u55ae\u85e5\u6cbb\u7642\u8a2d\u5b9a\uff08\u73fe\u66f4\u6709\u5169\u4efd\u8fd1\u671f\u767c\u8868\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u6587\u737b\u652f\u6301, \uff09\uff0c\u4ee5\u53ca\u5982 SABCS \u767c\u8868\u6578\u64da\u6240\u5f37\u8abf\uff0c\u5176\u5728\u806f\u5408\u6cbb\u7642\u65b9\u6848\u4e2d\u65e5\u76ca\u589e\u9577\u7684\u6f5b\u529b\u3002\u300dMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff0c\u300c\u6211\u5011\u81f4\u529b\u900f\u904e\u591a\u9805\u91dd\u5c0d\u65e9\u671f\u53ca\u8f49\u79fb\u6027\u4e73\u764c\u7684\u9032\u884c\u4e2d\u8a66\u9a57\uff0c\u5168\u9762\u63a2\u7d22 elacestrant \u7684\u6f5b\u5728\u6548\u76ca\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6 elacestrant \u7684\u66f4\u65b0\u8cc7\u8a0a\u4ea6\u5c07\u65bc SABCS \u767c\u8868\uff0c\u63a2\u8a0e\u5176\u5728\u5404\u985e\u4e73\u764c\u6cbb\u7642\u4e2d\u7684\u6f5b\u529b\uff1a \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u6cbb\u7642 ER+\\\/HER2- \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\uff1aELEVATE \u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\u7684\u7b2c 2 \u671f\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a1255\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 1:00 \u2013 2:00\u5730\u9ede\uff1aHemisfair 1-2 \u767c\u8868\u6f14\u8b1b\u8005\uff1a Hope S. Rugo \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u55ae\u85e5\u6216\u806f\u5408 triptorelin \u6cbb\u7642 ER+\\\/HER2- \u65e9\u671f\u4e73\u764c\u7d55\u7d93\u524d\u5973\u6027\uff1aSOLTI-2104-Premi\u00c8Re \u7b2c 2 \u671f\u8a66\u9a57\u7684\u4e3b\u8981\u5206\u6790\u6458\u8981\u7de8\u865f\uff1a1123\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0a\u5348 7:30 \u2013 7:33\u5730\u9ede\uff1a301 ABC\u767c\u8868\u6f14\u8b1b\u8005\uff1aMertixell Bellet \u7c21\u5831\u984c\u76ee\uff1aELEGANT\uff1a\u4e00\u9805\u5728\u5168\u7403\u591a\u4e2d\u5fc3\u9032\u884c\u7684\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\uff0c\u6bd4\u8f03 Elacestrant \u8207\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5728\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c (eBC) \u5973\u6027\u53ca\u7537\u6027\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1276\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAditya Bardia \u7c21\u5831\u984c\u76ee\uff1a ADELA \u7814\u7a76\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u6bd4\u8f03 Elacestrant (ELA) + Everolimus (EVE) \u5c0d\u6bd4 ELA + \u5b89\u6170\u5291 (PBO) \u5728\u66fe\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u53ca CDK4\\\/6 \u6291\u5236\u5291\u5f8c\u75c5\u60c5\u60e1\u5316\u4e14\u5e36\u6709 ESR1 \u7a81\u8b8a\u816b\u7624\u7684 ER+\\\/HER2- \u665a\u671f\u4e73\u764c (aBC) \u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1141\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 10 \u65e5\uff08\u661f\u671f\u4e09\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAntonio Llombart-Cussac \u7c21\u5831\u984c\u76ee\uff1aERADICATE\uff1a\u4e00\u9805\u7b2c Ib\\\/II \u671f\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u806f\u5408 trastuzumab deruxtecan \u6cbb\u7642\u5c0d CDK4\\\/6 \u6291\u5236\u5291\u53ca\u5167\u5206\u6ccc\u6cbb\u7642\u7522\u751f\u6297\u85e5\u6027\u7684 HR+\\\/HER2-\u4f4e\u8868\u9054 (low) \u6216 HER2-\u8d85\u4f4e\u8868\u9054 (ultralow) \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002\u6458\u8981\u7de8\u865f\uff1a2119\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1a Henry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aSara L. Sammons \u7c21\u5831\u984c\u76ee\uff1a\u8853\u524d\u63a5\u53d7 Elacestrant \u53ca PULSAR \u81ea\u9069\u61c9\u653e\u5c04\u6cbb\u7642\u7684\u8377\u723e\u8499\u53d7\u9ad4 (HR) \u967d\u6027 HER2 \u9670\u6027\u4e73\u764c\u60a3\u8005\uff1a\u4e00\u9805\u7b2c II \u671f\u7814\u7a76 (HELP \u8a66\u9a57) \u6458\u8981\u7de8\u865f\uff1a1071\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aLuca Visani \u95dc\u65bc Elacestrant Clinical Development Program \u6b64\u5916\uff0c\u8a72\u516c\u53f8\u4e5f\u8d0a\u52a9\u591a\u9805\u8f49\u79fb\u6027\u4e73\u764c\u7684\u81e8\u5e8a\u8a66\u9a57\uff0c\u63a2\u8a0e elacestrant \u55ae\u7368\u6216\u7d50\u5408\u5176\u4ed6\u7642\u6cd5\u7684\u6cbb\u7642\u3002ELEVATE (NCT05563220) \u662f\u7b2c 1b\\\/2 \u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 alpelisib\u3001everolimus\u3001capivasertib\u3001palbociclib\u3001ribociclib \u6216 abemaciclib \u7684\u5b89\u5168\u8207\u7642\u6548\u3002ELECTRA (NCT05386108) \u662f\u7b2c 1b\\\/2 \u671f\u3001\u958b\u653e\u6a19\u7c64\u517c\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 abemaciclib \u670d\u7528\uff0c\u5c0d ER+ \u548c HER2- \u4e73\u764c\u60a3\u8005\u7684\u6548\u679c\u3002\u7b2c 2 \u968e\u6bb5\u5247\u8a55\u4f30\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6cbb\u7642\u65b9\u6848\u3002ELCIN (NCT05596409) \u662f\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u5c0d ER+ \u548c HER2- \u665a\u671f\\\/\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\u3002\u9019\u4e9b\u60a3\u8005\u66fe\u63a5\u53d7\u4e00\u81f3\u5169\u7a2e\u8377\u723e\u8499\u7642\u6cd5\uff0c\u4f46\u5728\u8f49\u79fb\u6027\u60c5\u6cc1\u4e2d\uff0c\u672a\u66fe\u670d\u7528 CDK4\\\/6 \u6291\u5236\u5291\u3002ADELA (NCT06382948) \u662f\u7b2c 3 \u671f\u3001\u96a8\u6a5f\u517c\u96d9\u76f2\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 everolimus \u6cbb\u7642 ER+ \u548c HER2- mBC \u53ca ESR1-mut \u816b\u7624\u60a3\u8005\u7684\u7642\u6548\u3002Elacestrant \u4e5f\u65bc\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\uff0c\u70ba\u8f49\u79fb\u6027\u4e73\u764c\u548c\u65e9\u671f\u75be\u75c5\u9032\u884c\u8a55\u4f30\u3002 \u95dc\u65bc ORSERDU (elacestrant)\u5728\u7f8e\u570b\u6838\u51c6\u7684\u9069\u61c9\u75c7\uff1aORSERDU (elacestrant) \u662f 345 \u6beb\u514b\u7247\u5291\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u6216\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ESR1) \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u517c\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u65bc\u63a5\u53d7\u81f3\u5c11\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u9032\u5c55\u3002 \u5982\u6b32\u4e86\u89e3\u7f8e\u570b\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u6599\uff0c\u8acb\u700f\u89bd www.orserdu.com\u3002 \u91cd\u8981\u5b89\u5168\u8cc7\u8a0a\u8b66\u544a\u548c\u6ce8\u610f\u4e8b\u9805 \u9ad8\u8102\u8840\u75c7\uff1a\u670d\u7528 ORSERDU \u7684\u60a3\u8005\u4e2d\uff0c\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 30% \u548c 27%\u3002\u7b2c 3 \u7d1a\u548c\u7b2c 4 \u7d1a\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 0.9% \u548c 2.2%\u3002\u958b\u59cb\u670d\u7528 ORSERDU \u524d\u548c\u670d\u7528\u671f\u9593\uff0c\u5b9a\u671f\u76e3\u6e2c\u8840\u8102\u72c0\u6cc1\u3002 \u80da\u80ce-\u80ce\u5152\u6bd2\u6027\uff1a\u6839\u64da\u52d5\u7269\u5be6\u9a57\u7d50\u679c\u53ca\u7576\u4e2d\u4f5c\u7528\u6a5f\u5236\uff0c\u5b55\u5a66\u670d\u7528 ORSERDU\uff0c\u53ef\u80fd\u5c0d\u80ce\u5152\u9020\u6210\u50b7\u5bb3\u3002\u8acb\u544a\u77e5\u5b55\u5a66\u548c\u80b2\u9f61\u5973\u6027\uff0c\u80ce\u5152\u53ef\u80fd\u9762\u5c0d\u7684\u98a8\u96aa\u3002\u5efa\u8b70\u80b2\u9f61\u5973\u6027\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u548c\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002\u5efa\u8b70\u6709\u751f\u80b2\u80fd\u529b\u5973\u6027\u4f34\u4fb6\u7684\u7537\u6027\u60a3\u8005\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002 \u4e0d\u826f\u53cd\u61c9 12% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\uff0c\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\u3002\u5728\u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0c\u8d85\u904e 1% \u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u808c\u8089\u9aa8\u9abc\u75bc\u75db (1.7%) \u548c\u5641\u5fc3 (1.3%)\u30021.7% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u51fa\u73fe\u81f4\u547d\u7684\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u5fc3\u81df\u9a5f\u505c\u3001\u6557\u8840\u6027\u4f11\u514b\u3001\u61a9\u5ba4\u708e\u548c\u539f\u56e0\u4e0d\u660e\u7684\u60c5\u6cc1\uff08\u5404\u4e00\u4f8b\uff09\u3002ORSERDU \u6700\u5e38\u898b\u7684\u4e0d\u826f\u53cd\u61c9 (&gt; 10%)\uff0c\u5305\u62ec\u5be6\u9a57\u5ba4\u7570\u5e38\uff0c\u662f\u808c\u8089\u9aa8\u9abc\u75bc\u75db (41%)\u3001\u5641\u5fc3 (35%)\u3001\u81bd\u56fa\u9187\u5347\u9ad8 (30%)\u3001AST \u589e\u52a0 (29%)\u3001\u7518\u6cb9\u4e09\u916f\u589e\u52a0 (27%)\u3001\u75b2\u52de (26%)\u3001\u8840\u7d05\u86cb\u767d\u4e0b\u964d (26%)\u3001\u5614\u5410 (19%)\u3001ALT \u589e\u9ad8 (17%)\u3001\u9209\u964d\u4f4e (16%)\u3001\u808c\u9178\u589e\u52a0 (16%)\u3001\u98df\u617e\u4e0b\u964d (15%)\u3001\u8179\u7009 (13%)\u3001\u982d\u75db (12%)\u3001\u4fbf\u79d8 (12%)\u3001\u8179\u75db (11%)\u3001\u6f6e\u71b1 (11%) \u548c\u6d88\u5316\u4e0d\u826f (10%)\u3002 \u85e5\u7269\u4ea4\u4e92\u53cd\u61c9 \u540c\u6642\u670d\u7528 CYP3A4 \u8a98\u5c0e\u5291\u548c\\\/\u6216\u6291\u5236\u5291\uff1a\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u6291\u5236\u5291\u548c ORSERDU\u3002\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u8a98\u5c0e\u5291\u548c ORSERDU\u3002 \u7279\u5b9a\u4eba\u58eb\u670d\u7528\u9808\u77e5 \u54fa\u4e73\u671f\uff1a\u5efa\u8b70\u54fa\u4e73\u5a66\u5973\u670d\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u5207\u52ff\u54fa\u4e73\u3002\u809d\u529f\u80fd\u53d7\u640d\uff1a\u5207\u52ff\u4e88\u56b4\u91cd\u809d\u529f\u80fd\u4e0d\u5168 (Child-Pugh C) \u7684\u60a3\u8005\u670d\u7528 ORSERDU\u3002\u5c0d\u65bc\u4e2d\u5ea6\u809d\u529f\u80fd\u4e0d\u5168\uff08Child-Pugh B\uff09\u7684\u60a3\u8005\uff0c\u61c9\u964d\u4f4e ORSERDU \u7684\u5291\u91cf\u3002\u5c1a\u672a\u78ba\u5b9a ORSERDU \u5c0d\u5152\u79d1\u60a3\u8005\u7684\u5b89\u5168\u548c\u6210\u6548\u3002 \u5982\u6b32\u5831\u544a\u61f7\u7591\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff08\u96fb\u8a71\uff1a1-877-332-7961\uff09\u6216\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\uff08\u96fb\u8a71\uff1a1-800-FDA-1088 \u6216\u7db2\u4e0a\u7559\u8a00\uff1awww.fda.gov\\\/medwatch\uff09\u3002 \u95dc\u65bc Menarini Group Menarini Group \u662f\u570b\u969b\u9818\u5148\u7684\u88fd\u85e5\u548c\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u9054 50 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u8d85\u904e 17,000 \u540d\u3002Menarini \u5c08\u6ce8\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u75c5\u5b78\u3001\u816b\u7624\u5b78\u3001\u80ba\u75c5\u5b78\u3001\u80c3\u8178\u75c5\u5b78\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u5b78\u3001\u767c\u708e\u548c\u93ae\u75db\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u904d\u4f48\u5168\u7403 140 \u500b\u570b\u5bb6\\\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 Stemline Therapeutics Inc. \u7c21\u4ecbMenarini Group \u5168\u8cc7\u5b50\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u662f\u4e00\u9593\u5546\u696d\u968e\u6bb5\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u70ba\u75c5\u4eba\u63d0\u4f9b\u5d84\u65b0\u816b\u7624\u6cbb\u7642\u3002Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316 elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u7684\u5df2\u505c\u7d93\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u63a5\u53d7\u6700\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u7642\u6cd5\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u60e1\u5316\u3002Stemline \u4e5f\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269 tagraxofusp-erzs\u3002\u9019\u85e5\u7269\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u72c0\u7d30\u80de\u816b\u7624 (BPDCN)\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002\u6b64\u5916\uff0cStemline \u65bc\u6b50\u6d32\u5546\u696d\u5316 selinexor\uff0c\u9019\u662f\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1\u6291\u5236\u5291\u3002\u8a72\u516c\u53f8\u9084\u5c31\u4e73\u764c\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u9069\u61c9\u75c7\uff0c\u5206\u5225\u5229\u7528 elacestrant \u548c tagraxofusp \u4f5c\u591a\u9805\u6a19\u7c64\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u70ba\u5be6\u9ad4\u764c\u75c7\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u75c5\u4eba\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\uff0c\u64c1\u6709\u8655\u65bc\u4e0d\u540c\u7814\u767c\u968e\u6bb5\u7684\u5ee3\u6cdb\u81e8\u5e8a\u7ba1\u7dda\u3002 Lloyd\u00a0et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).\u00a0https:\\\/\\\/aacrjournals.org\\\/clincancerres\\\/article\\\/doi\\\/10.1158\\\/1078-0432.CCR-25-3033\\\/768341\\\/Clinical-and-Genomic-Factors-Associated-with Rugo et al.\u00a0Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. \u00a0Clin Cancer Res, 2025. CCR-25-3040R1.\u00a0https:\\\/\\\/aacrjournals.org\\\/clincancerres\\\/article\\\/doi\\\/10.1158\\\/1078-0432.CCR-25-3040\\\/768340\\\/Real-World-Outcomes-of-Elacestrant-in-ER-HER2-ESR1\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg\",\"width\":400,\"height\":121},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=391065#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u6b64\u5916\uff0celacestrant \u5ee3\u6cdb\u7684\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u6700\u65b0\u9032\u5c55\uff0c\u9032\u4e00\u6b65\u978f\u56fa\u5176\u4f5c\u70ba\u806f\u5408\u6cbb\u7642\u3001\u4ee5\u53ca\u8f49\u79fb\u6027\u548c\u65e9\u671f\u4e73\u764c\u6cbb\u7642\u4e2d\u9aa8\u5e79\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u6f5b\u529b\u3002   \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042025\u5e7412\u670810\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u7684\u85e5\u696d\u53ca\u8a3a\u65b7\u516c\u53f8 Menarini Group\uff08\u4e0b\u7a31\u300cMenarini\u300d\uff09\uff0c\u8207\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u8b8a\u9769\u6027\u816b\u7624\u7642\u6cd5\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u4e0b\u7a31\u300cStemline\u300d\uff09\uff0c\u5ba3\u4f48\u5c07\u516c\u4f48\u7b2c 2 \u671f ELEVATE \u7814\u7a76\u4e2d\u5169\u9805\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u6700\u65b0\u5177\u81e8\u5e8a\u610f\u7fa9\u7684\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7642\u6548\u7d50\u679c\uff0c\u8a72\u7814\u7a76\u91dd\u5c0d\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u3002ELEVATE \u7814\u7a76\u65e8\u5728\u8a55\u4f30\u5168\u53e3\u670d\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u85c9\u4ee5\u514b\u670d ER+\/HER2- mBC \u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6a5f\u5236\uff0c\u5f9e\u800c\u6539\u5584\u60a3\u8005\u7684\u6cbb\u7642\u6210\u6548\u3002\u76f8\u95dc\u6578\u64da\u5c07\u65bc 12 \u6708 9 \u65e5\u81f3 12 \u65e5\u8209\u884c\u7684 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u767c\u8868\u3002 \u300c\u4ee4\u4eba\u9f13\u821e\u7684\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u589e\u5f37\u4e86\u6211\u5011\u5c0d elacestrant \u5728\u806f\u5408\u6cbb\u7642\u4e2d\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642\u9aa8\u5e79\u89d2\u8272\u7684\u4fe1\u5fc3\u3002\u300d\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821\u5065\u5eb7\u79d1\u5b78\u4e2d\u5fc3\u8840\u6db2\u5b78\/\u816b\u7624\u79d1\u91ab\u5b78\u6559\u6388\u517c\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821 MD \u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u4e73\u764c\u9805\u76ee\u8ca0\u8cac\u4eba Virginia Kaklamani \u91ab\u5b78\u535a\u58eb\u8868\u793a\uff0c\u00a0\u300cElacestrant \u8207 everolimus \u6216 abemaciclib \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u7279\u5fb5\uff0c\u8207\u6bcf\u7a2e\u85e5\u7269\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002\u4e26\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u8a0a\u865f\u3002\u300d \u5c07\u65bc SABCS \u767c\u8868\u7684 ELEVATE \u6578\u64da\u986f\u793a\uff0c\u5c0d\u65bc\u66fe\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5f8c\u75c5\u60c5\u60e1\u5316\uff08\u4e0d\u8ad6\u662f\u5426\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\uff09\u7684 ER+\/HER2- mBC \u60a3\u8005\uff0celacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u5747\u986f\u793a\u51fa\u4e00\u81f4\u7684 PFS \u6548\u76ca\uff0c\u4e14\u4e0d\u53d7 ESR1 \u7a81\u8b8a\u72c0\u614b\u5f71\u97ff\u3002\u6700\u65b0\u7d50\u679c\u4ea6\u986f\u793a\uff0c\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8207\u5404\u6a19\u9776\u7642\u6cd5\u52a0\u4e0a\u6a19\u6e96\u8b77\u7406\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u5df2\u77e5\u5b89\u5168\u6027\u4e00\u81f4\u3002 \u7b2c 2 \u671f mPFS\uff08\u6708\uff09\uff0895% \u7f6e\u4fe1\u5340\u9593 \uff09\uff0c\u6db5\u84cb\u6240\u6709\u60a3\u8005\u53ca\u4e9e\u7d44          \u60a3\u8005\u7fa4\u9ad4    Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Everolimus 7.5mg \u6bcf\u65e5\u4e00\u6b21 (n = 50)    Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Abemaciclib 150 mg \u6bcf\u65e5\u5169\u6b21 (n = 60)         \u6240\u6709\u60a3\u8005    8.3    14.3         \u5167\u81df\u8f49\u79fb    7.7    14.3         \u672a\u66fe\u63a5\u53d7 fulvestrant \u6cbb\u7642    8.3    14.8         \u7121\u539f\u767c\u6027\u5167\u5206\u6ccc\u6297\u85e5\u6027    8.3    14.3         ESR1\u7a81\u8b8a    8.7    *         ESR1\u91ce\u751f\u578b    9.0    *         PIK3CA\u7a81\u8b8a    8.3    *         PIK3CA\u91ce\u751f\u578b    9.6    *         *Elacestrant + abemaciclib \u968a\u5217\u4e2d\u7684\u57fa\u56e0\u7d44\u4e9e\u7d44 (ESR1 \/ PIK3CA) \u4e4b PFS \u5c1a\u672a\u6210\u719f (95% CI)\u3002         \u00a0 \u300cElacestrant \u64c1\u6709\u5ee3\u6cdb\u7684\u8b49\u64da\u652f\u6301\uff0c\u6db5\u84cb\u4e86\u6211\u5011\u95dc\u9375 EMERALD \u7814\u7a76\u4e2d\u7684\u55ae\u85e5\u6cbb\u7642\u8a2d\u5b9a\uff08\u73fe\u66f4\u6709\u5169\u4efd\u8fd1\u671f\u767c\u8868\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u6587\u737b\u652f\u6301, \uff09\uff0c\u4ee5\u53ca\u5982 SABCS \u767c\u8868\u6578\u64da\u6240\u5f37\u8abf\uff0c\u5176\u5728\u806f\u5408\u6cbb\u7642\u65b9\u6848\u4e2d\u65e5\u76ca\u589e\u9577\u7684\u6f5b\u529b\u3002\u300dMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff0c\u300c\u6211\u5011\u81f4\u529b\u900f\u904e\u591a\u9805\u91dd\u5c0d\u65e9\u671f\u53ca\u8f49\u79fb\u6027\u4e73\u764c\u7684\u9032\u884c\u4e2d\u8a66\u9a57\uff0c\u5168\u9762\u63a2\u7d22 elacestrant \u7684\u6f5b\u5728\u6548\u76ca\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6 elacestrant \u7684\u66f4\u65b0\u8cc7\u8a0a\u4ea6\u5c07\u65bc SABCS \u767c\u8868\uff0c\u63a2\u8a0e\u5176\u5728\u5404\u985e\u4e73\u764c\u6cbb\u7642\u4e2d\u7684\u6f5b\u529b\uff1a \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u6cbb\u7642 ER+\/HER2- \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\uff1aELEVATE \u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\u7684\u7b2c 2 \u671f\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a1255\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 1:00 \u2013 2:00\u5730\u9ede\uff1aHemisfair 1-2 \u767c\u8868\u6f14\u8b1b\u8005\uff1a Hope S. Rugo \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u55ae\u85e5\u6216\u806f\u5408 triptorelin \u6cbb\u7642 ER+\/HER2- \u65e9\u671f\u4e73\u764c\u7d55\u7d93\u524d\u5973\u6027\uff1aSOLTI-2104-Premi\u00c8Re \u7b2c 2 \u671f\u8a66\u9a57\u7684\u4e3b\u8981\u5206\u6790\u6458\u8981\u7de8\u865f\uff1a1123\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0a\u5348 7:30 \u2013 7:33\u5730\u9ede\uff1a301 ABC\u767c\u8868\u6f14\u8b1b\u8005\uff1aMertixell Bellet \u7c21\u5831\u984c\u76ee\uff1aELEGANT\uff1a\u4e00\u9805\u5728\u5168\u7403\u591a\u4e2d\u5fc3\u9032\u884c\u7684\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\uff0c\u6bd4\u8f03 Elacestrant \u8207\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5728\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c (eBC) \u5973\u6027\u53ca\u7537\u6027\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1276\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAditya Bardia \u7c21\u5831\u984c\u76ee\uff1a ADELA \u7814\u7a76\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u6bd4\u8f03 Elacestrant (ELA) + Everolimus (EVE) \u5c0d\u6bd4 ELA + \u5b89\u6170\u5291 (PBO) \u5728\u66fe\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u53ca CDK4\/6 \u6291\u5236\u5291\u5f8c\u75c5\u60c5\u60e1\u5316\u4e14\u5e36\u6709 ESR1 \u7a81\u8b8a\u816b\u7624\u7684 ER+\/HER2- \u665a\u671f\u4e73\u764c (aBC) \u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1141\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 10 \u65e5\uff08\u661f\u671f\u4e09\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAntonio Llombart-Cussac \u7c21\u5831\u984c\u76ee\uff1aERADICATE\uff1a\u4e00\u9805\u7b2c Ib\/II \u671f\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u806f\u5408 trastuzumab deruxtecan \u6cbb\u7642\u5c0d CDK4\/6 \u6291\u5236\u5291\u53ca\u5167\u5206\u6ccc\u6cbb\u7642\u7522\u751f\u6297\u85e5\u6027\u7684 HR+\/HER2-\u4f4e\u8868\u9054 (low) \u6216 HER2-\u8d85\u4f4e\u8868\u9054 (ultralow) \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002\u6458\u8981\u7de8\u865f\uff1a2119\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1a Henry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aSara L. Sammons \u7c21\u5831\u984c\u76ee\uff1a\u8853\u524d\u63a5\u53d7 Elacestrant \u53ca PULSAR \u81ea\u9069\u61c9\u653e\u5c04\u6cbb\u7642\u7684\u8377\u723e\u8499\u53d7\u9ad4 (HR) \u967d\u6027 HER2 \u9670\u6027\u4e73\u764c\u60a3\u8005\uff1a\u4e00\u9805\u7b2c II \u671f\u7814\u7a76 (HELP \u8a66\u9a57) \u6458\u8981\u7de8\u865f\uff1a1071\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aLuca Visani \u95dc\u65bc Elacestrant Clinical Development Program \u6b64\u5916\uff0c\u8a72\u516c\u53f8\u4e5f\u8d0a\u52a9\u591a\u9805\u8f49\u79fb\u6027\u4e73\u764c\u7684\u81e8\u5e8a\u8a66\u9a57\uff0c\u63a2\u8a0e elacestrant \u55ae\u7368\u6216\u7d50\u5408\u5176\u4ed6\u7642\u6cd5\u7684\u6cbb\u7642\u3002ELEVATE (NCT05563220) \u662f\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 alpelisib\u3001everolimus\u3001capivasertib\u3001palbociclib\u3001ribociclib \u6216 abemaciclib \u7684\u5b89\u5168\u8207\u7642\u6548\u3002ELECTRA (NCT05386108) \u662f\u7b2c 1b\/2 \u671f\u3001\u958b\u653e\u6a19\u7c64\u517c\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 abemaciclib \u670d\u7528\uff0c\u5c0d ER+ \u548c HER2- \u4e73\u764c\u60a3\u8005\u7684\u6548\u679c\u3002\u7b2c 2 \u968e\u6bb5\u5247\u8a55\u4f30\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6cbb\u7642\u65b9\u6848\u3002ELCIN (NCT05596409) \u662f\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u5c0d ER+ \u548c HER2- \u665a\u671f\/\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\u3002\u9019\u4e9b\u60a3\u8005\u66fe\u63a5\u53d7\u4e00\u81f3\u5169\u7a2e\u8377\u723e\u8499\u7642\u6cd5\uff0c\u4f46\u5728\u8f49\u79fb\u6027\u60c5\u6cc1\u4e2d\uff0c\u672a\u66fe\u670d\u7528 CDK4\/6 \u6291\u5236\u5291\u3002ADELA (NCT06382948) \u662f\u7b2c 3 \u671f\u3001\u96a8\u6a5f\u517c\u96d9\u76f2\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 everolimus \u6cbb\u7642 ER+ \u548c HER2- mBC \u53ca ESR1-mut \u816b\u7624\u60a3\u8005\u7684\u7642\u6548\u3002Elacestrant \u4e5f\u65bc\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\uff0c\u70ba\u8f49\u79fb\u6027\u4e73\u764c\u548c\u65e9\u671f\u75be\u75c5\u9032\u884c\u8a55\u4f30\u3002 \u95dc\u65bc ORSERDU (elacestrant)\u5728\u7f8e\u570b\u6838\u51c6\u7684\u9069\u61c9\u75c7\uff1aORSERDU (elacestrant) \u662f 345 \u6beb\u514b\u7247\u5291\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u6216\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ESR1) \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u517c\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u65bc\u63a5\u53d7\u81f3\u5c11\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u9032\u5c55\u3002 \u5982\u6b32\u4e86\u89e3\u7f8e\u570b\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u6599\uff0c\u8acb\u700f\u89bd www.orserdu.com\u3002 \u91cd\u8981\u5b89\u5168\u8cc7\u8a0a\u8b66\u544a\u548c\u6ce8\u610f\u4e8b\u9805 \u9ad8\u8102\u8840\u75c7\uff1a\u670d\u7528 ORSERDU \u7684\u60a3\u8005\u4e2d\uff0c\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 30% \u548c 27%\u3002\u7b2c 3 \u7d1a\u548c\u7b2c 4 \u7d1a\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 0.9% \u548c 2.2%\u3002\u958b\u59cb\u670d\u7528 ORSERDU \u524d\u548c\u670d\u7528\u671f\u9593\uff0c\u5b9a\u671f\u76e3\u6e2c\u8840\u8102\u72c0\u6cc1\u3002 \u80da\u80ce-\u80ce\u5152\u6bd2\u6027\uff1a\u6839\u64da\u52d5\u7269\u5be6\u9a57\u7d50\u679c\u53ca\u7576\u4e2d\u4f5c\u7528\u6a5f\u5236\uff0c\u5b55\u5a66\u670d\u7528 ORSERDU\uff0c\u53ef\u80fd\u5c0d\u80ce\u5152\u9020\u6210\u50b7\u5bb3\u3002\u8acb\u544a\u77e5\u5b55\u5a66\u548c\u80b2\u9f61\u5973\u6027\uff0c\u80ce\u5152\u53ef\u80fd\u9762\u5c0d\u7684\u98a8\u96aa\u3002\u5efa\u8b70\u80b2\u9f61\u5973\u6027\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u548c\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002\u5efa\u8b70\u6709\u751f\u80b2\u80fd\u529b\u5973\u6027\u4f34\u4fb6\u7684\u7537\u6027\u60a3\u8005\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002 \u4e0d\u826f\u53cd\u61c9 12% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\uff0c\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\u3002\u5728\u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0c\u8d85\u904e 1% \u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u808c\u8089\u9aa8\u9abc\u75bc\u75db (1.7%) \u548c\u5641\u5fc3 (1.3%)\u30021.7% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u51fa\u73fe\u81f4\u547d\u7684\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u5fc3\u81df\u9a5f\u505c\u3001\u6557\u8840\u6027\u4f11\u514b\u3001\u61a9\u5ba4\u708e\u548c\u539f\u56e0\u4e0d\u660e\u7684\u60c5\u6cc1\uff08\u5404\u4e00\u4f8b\uff09\u3002ORSERDU \u6700\u5e38\u898b\u7684\u4e0d\u826f\u53cd\u61c9 (&gt; 10%)\uff0c\u5305\u62ec\u5be6\u9a57\u5ba4\u7570\u5e38\uff0c\u662f\u808c\u8089\u9aa8\u9abc\u75bc\u75db (41%)\u3001\u5641\u5fc3 (35%)\u3001\u81bd\u56fa\u9187\u5347\u9ad8 (30%)\u3001AST \u589e\u52a0 (29%)\u3001\u7518\u6cb9\u4e09\u916f\u589e\u52a0 (27%)\u3001\u75b2\u52de (26%)\u3001\u8840\u7d05\u86cb\u767d\u4e0b\u964d (26%)\u3001\u5614\u5410 (19%)\u3001ALT \u589e\u9ad8 (17%)\u3001\u9209\u964d\u4f4e (16%)\u3001\u808c\u9178\u589e\u52a0 (16%)\u3001\u98df\u617e\u4e0b\u964d (15%)\u3001\u8179\u7009 (13%)\u3001\u982d\u75db (12%)\u3001\u4fbf\u79d8 (12%)\u3001\u8179\u75db (11%)\u3001\u6f6e\u71b1 (11%) \u548c\u6d88\u5316\u4e0d\u826f (10%)\u3002 \u85e5\u7269\u4ea4\u4e92\u53cd\u61c9 \u540c\u6642\u670d\u7528 CYP3A4 \u8a98\u5c0e\u5291\u548c\/\u6216\u6291\u5236\u5291\uff1a\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u6291\u5236\u5291\u548c ORSERDU\u3002\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u8a98\u5c0e\u5291\u548c ORSERDU\u3002 \u7279\u5b9a\u4eba\u58eb\u670d\u7528\u9808\u77e5 \u54fa\u4e73\u671f\uff1a\u5efa\u8b70\u54fa\u4e73\u5a66\u5973\u670d\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u5207\u52ff\u54fa\u4e73\u3002\u809d\u529f\u80fd\u53d7\u640d\uff1a\u5207\u52ff\u4e88\u56b4\u91cd\u809d\u529f\u80fd\u4e0d\u5168 (Child-Pugh C) \u7684\u60a3\u8005\u670d\u7528 ORSERDU\u3002\u5c0d\u65bc\u4e2d\u5ea6\u809d\u529f\u80fd\u4e0d\u5168\uff08Child-Pugh B\uff09\u7684\u60a3\u8005\uff0c\u61c9\u964d\u4f4e ORSERDU \u7684\u5291\u91cf\u3002\u5c1a\u672a\u78ba\u5b9a ORSERDU \u5c0d\u5152\u79d1\u60a3\u8005\u7684\u5b89\u5168\u548c\u6210\u6548\u3002 \u5982\u6b32\u5831\u544a\u61f7\u7591\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff08\u96fb\u8a71\uff1a1-877-332-7961\uff09\u6216\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\uff08\u96fb\u8a71\uff1a1-800-FDA-1088 \u6216\u7db2\u4e0a\u7559\u8a00\uff1awww.fda.gov\/medwatch\uff09\u3002 \u95dc\u65bc Menarini Group Menarini Group \u662f\u570b\u969b\u9818\u5148\u7684\u88fd\u85e5\u548c\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u9054 50 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u8d85\u904e 17,000 \u540d\u3002Menarini \u5c08\u6ce8\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u75c5\u5b78\u3001\u816b\u7624\u5b78\u3001\u80ba\u75c5\u5b78\u3001\u80c3\u8178\u75c5\u5b78\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u5b78\u3001\u767c\u708e\u548c\u93ae\u75db\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u904d\u4f48\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 Stemline Therapeutics Inc. \u7c21\u4ecbMenarini Group \u5168\u8cc7\u5b50\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u662f\u4e00\u9593\u5546\u696d\u968e\u6bb5\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u70ba\u75c5\u4eba\u63d0\u4f9b\u5d84\u65b0\u816b\u7624\u6cbb\u7642\u3002Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316 elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u7684\u5df2\u505c\u7d93\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u63a5\u53d7\u6700\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u7642\u6cd5\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u60e1\u5316\u3002Stemline \u4e5f\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269 tagraxofusp-erzs\u3002\u9019\u85e5\u7269\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u72c0\u7d30\u80de\u816b\u7624 (BPDCN)\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002\u6b64\u5916\uff0cStemline \u65bc\u6b50\u6d32\u5546\u696d\u5316 selinexor\uff0c\u9019\u662f\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1\u6291\u5236\u5291\u3002\u8a72\u516c\u53f8\u9084\u5c31\u4e73\u764c\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u9069\u61c9\u75c7\uff0c\u5206\u5225\u5229\u7528 elacestrant \u548c tagraxofusp \u4f5c\u591a\u9805\u6a19\u7c64\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u70ba\u5be6\u9ad4\u764c\u75c7\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u75c5\u4eba\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\uff0c\u64c1\u6709\u8655\u65bc\u4e0d\u540c\u7814\u767c\u968e\u6bb5\u7684\u5ee3\u6cdb\u81e8\u5e8a\u7ba1\u7dda\u3002  Lloyd\u00a0et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3033\/768341\/Clinical-and-Genomic-Factors-Associated-with  Rugo et al.\u00a0Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. \u00a0Clin Cancer Res, 2025. CCR-25-3040R1.\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3040\/768340\/Real-World-Outcomes-of-Elacestrant-in-ER-HER2-ESR1","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=391065","og_locale":"zh_TW","og_type":"article","og_title":"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u6b64\u5916\uff0celacestrant \u5ee3\u6cdb\u7684\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u6700\u65b0\u9032\u5c55\uff0c\u9032\u4e00\u6b65\u978f\u56fa\u5176\u4f5c\u70ba\u806f\u5408\u6cbb\u7642\u3001\u4ee5\u53ca\u8f49\u79fb\u6027\u548c\u65e9\u671f\u4e73\u764c\u6cbb\u7642\u4e2d\u9aa8\u5e79\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u6f5b\u529b\u3002   \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042025\u5e7412\u670810\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u7684\u85e5\u696d\u53ca\u8a3a\u65b7\u516c\u53f8 Menarini Group\uff08\u4e0b\u7a31\u300cMenarini\u300d\uff09\uff0c\u8207\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u8b8a\u9769\u6027\u816b\u7624\u7642\u6cd5\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u4e0b\u7a31\u300cStemline\u300d\uff09\uff0c\u5ba3\u4f48\u5c07\u516c\u4f48\u7b2c 2 \u671f ELEVATE \u7814\u7a76\u4e2d\u5169\u9805\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u6700\u65b0\u5177\u81e8\u5e8a\u610f\u7fa9\u7684\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7642\u6548\u7d50\u679c\uff0c\u8a72\u7814\u7a76\u91dd\u5c0d\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u3002ELEVATE \u7814\u7a76\u65e8\u5728\u8a55\u4f30\u5168\u53e3\u670d\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u85c9\u4ee5\u514b\u670d ER+\/HER2- mBC \u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6a5f\u5236\uff0c\u5f9e\u800c\u6539\u5584\u60a3\u8005\u7684\u6cbb\u7642\u6210\u6548\u3002\u76f8\u95dc\u6578\u64da\u5c07\u65bc 12 \u6708 9 \u65e5\u81f3 12 \u65e5\u8209\u884c\u7684 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u767c\u8868\u3002 \u300c\u4ee4\u4eba\u9f13\u821e\u7684\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u589e\u5f37\u4e86\u6211\u5011\u5c0d elacestrant \u5728\u806f\u5408\u6cbb\u7642\u4e2d\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642\u9aa8\u5e79\u89d2\u8272\u7684\u4fe1\u5fc3\u3002\u300d\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821\u5065\u5eb7\u79d1\u5b78\u4e2d\u5fc3\u8840\u6db2\u5b78\/\u816b\u7624\u79d1\u91ab\u5b78\u6559\u6388\u517c\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821 MD \u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u4e73\u764c\u9805\u76ee\u8ca0\u8cac\u4eba Virginia Kaklamani \u91ab\u5b78\u535a\u58eb\u8868\u793a\uff0c\u00a0\u300cElacestrant \u8207 everolimus \u6216 abemaciclib \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u7279\u5fb5\uff0c\u8207\u6bcf\u7a2e\u85e5\u7269\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002\u4e26\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u8a0a\u865f\u3002\u300d \u5c07\u65bc SABCS \u767c\u8868\u7684 ELEVATE \u6578\u64da\u986f\u793a\uff0c\u5c0d\u65bc\u66fe\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5f8c\u75c5\u60c5\u60e1\u5316\uff08\u4e0d\u8ad6\u662f\u5426\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\uff09\u7684 ER+\/HER2- mBC \u60a3\u8005\uff0celacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u5747\u986f\u793a\u51fa\u4e00\u81f4\u7684 PFS \u6548\u76ca\uff0c\u4e14\u4e0d\u53d7 ESR1 \u7a81\u8b8a\u72c0\u614b\u5f71\u97ff\u3002\u6700\u65b0\u7d50\u679c\u4ea6\u986f\u793a\uff0c\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8207\u5404\u6a19\u9776\u7642\u6cd5\u52a0\u4e0a\u6a19\u6e96\u8b77\u7406\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u5df2\u77e5\u5b89\u5168\u6027\u4e00\u81f4\u3002 \u7b2c 2 \u671f mPFS\uff08\u6708\uff09\uff0895% \u7f6e\u4fe1\u5340\u9593 \uff09\uff0c\u6db5\u84cb\u6240\u6709\u60a3\u8005\u53ca\u4e9e\u7d44          \u60a3\u8005\u7fa4\u9ad4    Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Everolimus 7.5mg \u6bcf\u65e5\u4e00\u6b21 (n = 50)    Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Abemaciclib 150 mg \u6bcf\u65e5\u5169\u6b21 (n = 60)         \u6240\u6709\u60a3\u8005    8.3    14.3         \u5167\u81df\u8f49\u79fb    7.7    14.3         \u672a\u66fe\u63a5\u53d7 fulvestrant \u6cbb\u7642    8.3    14.8         \u7121\u539f\u767c\u6027\u5167\u5206\u6ccc\u6297\u85e5\u6027    8.3    14.3         ESR1\u7a81\u8b8a    8.7    *         ESR1\u91ce\u751f\u578b    9.0    *         PIK3CA\u7a81\u8b8a    8.3    *         PIK3CA\u91ce\u751f\u578b    9.6    *         *Elacestrant + abemaciclib \u968a\u5217\u4e2d\u7684\u57fa\u56e0\u7d44\u4e9e\u7d44 (ESR1 \/ PIK3CA) \u4e4b PFS \u5c1a\u672a\u6210\u719f (95% CI)\u3002         \u00a0 \u300cElacestrant \u64c1\u6709\u5ee3\u6cdb\u7684\u8b49\u64da\u652f\u6301\uff0c\u6db5\u84cb\u4e86\u6211\u5011\u95dc\u9375 EMERALD \u7814\u7a76\u4e2d\u7684\u55ae\u85e5\u6cbb\u7642\u8a2d\u5b9a\uff08\u73fe\u66f4\u6709\u5169\u4efd\u8fd1\u671f\u767c\u8868\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u6587\u737b\u652f\u6301, \uff09\uff0c\u4ee5\u53ca\u5982 SABCS \u767c\u8868\u6578\u64da\u6240\u5f37\u8abf\uff0c\u5176\u5728\u806f\u5408\u6cbb\u7642\u65b9\u6848\u4e2d\u65e5\u76ca\u589e\u9577\u7684\u6f5b\u529b\u3002\u300dMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff0c\u300c\u6211\u5011\u81f4\u529b\u900f\u904e\u591a\u9805\u91dd\u5c0d\u65e9\u671f\u53ca\u8f49\u79fb\u6027\u4e73\u764c\u7684\u9032\u884c\u4e2d\u8a66\u9a57\uff0c\u5168\u9762\u63a2\u7d22 elacestrant \u7684\u6f5b\u5728\u6548\u76ca\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6 elacestrant \u7684\u66f4\u65b0\u8cc7\u8a0a\u4ea6\u5c07\u65bc SABCS \u767c\u8868\uff0c\u63a2\u8a0e\u5176\u5728\u5404\u985e\u4e73\u764c\u6cbb\u7642\u4e2d\u7684\u6f5b\u529b\uff1a \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u6cbb\u7642 ER+\/HER2- \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\uff1aELEVATE \u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\u7684\u7b2c 2 \u671f\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a1255\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 1:00 \u2013 2:00\u5730\u9ede\uff1aHemisfair 1-2 \u767c\u8868\u6f14\u8b1b\u8005\uff1a Hope S. Rugo \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u55ae\u85e5\u6216\u806f\u5408 triptorelin \u6cbb\u7642 ER+\/HER2- \u65e9\u671f\u4e73\u764c\u7d55\u7d93\u524d\u5973\u6027\uff1aSOLTI-2104-Premi\u00c8Re \u7b2c 2 \u671f\u8a66\u9a57\u7684\u4e3b\u8981\u5206\u6790\u6458\u8981\u7de8\u865f\uff1a1123\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0a\u5348 7:30 \u2013 7:33\u5730\u9ede\uff1a301 ABC\u767c\u8868\u6f14\u8b1b\u8005\uff1aMertixell Bellet \u7c21\u5831\u984c\u76ee\uff1aELEGANT\uff1a\u4e00\u9805\u5728\u5168\u7403\u591a\u4e2d\u5fc3\u9032\u884c\u7684\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\uff0c\u6bd4\u8f03 Elacestrant \u8207\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5728\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c (eBC) \u5973\u6027\u53ca\u7537\u6027\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1276\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAditya Bardia \u7c21\u5831\u984c\u76ee\uff1a ADELA \u7814\u7a76\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u6bd4\u8f03 Elacestrant (ELA) + Everolimus (EVE) \u5c0d\u6bd4 ELA + \u5b89\u6170\u5291 (PBO) \u5728\u66fe\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u53ca CDK4\/6 \u6291\u5236\u5291\u5f8c\u75c5\u60c5\u60e1\u5316\u4e14\u5e36\u6709 ESR1 \u7a81\u8b8a\u816b\u7624\u7684 ER+\/HER2- \u665a\u671f\u4e73\u764c (aBC) \u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1141\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 10 \u65e5\uff08\u661f\u671f\u4e09\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAntonio Llombart-Cussac \u7c21\u5831\u984c\u76ee\uff1aERADICATE\uff1a\u4e00\u9805\u7b2c Ib\/II \u671f\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u806f\u5408 trastuzumab deruxtecan \u6cbb\u7642\u5c0d CDK4\/6 \u6291\u5236\u5291\u53ca\u5167\u5206\u6ccc\u6cbb\u7642\u7522\u751f\u6297\u85e5\u6027\u7684 HR+\/HER2-\u4f4e\u8868\u9054 (low) \u6216 HER2-\u8d85\u4f4e\u8868\u9054 (ultralow) \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002\u6458\u8981\u7de8\u865f\uff1a2119\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1a Henry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aSara L. Sammons \u7c21\u5831\u984c\u76ee\uff1a\u8853\u524d\u63a5\u53d7 Elacestrant \u53ca PULSAR \u81ea\u9069\u61c9\u653e\u5c04\u6cbb\u7642\u7684\u8377\u723e\u8499\u53d7\u9ad4 (HR) \u967d\u6027 HER2 \u9670\u6027\u4e73\u764c\u60a3\u8005\uff1a\u4e00\u9805\u7b2c II \u671f\u7814\u7a76 (HELP \u8a66\u9a57) \u6458\u8981\u7de8\u865f\uff1a1071\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aLuca Visani \u95dc\u65bc Elacestrant Clinical Development Program \u6b64\u5916\uff0c\u8a72\u516c\u53f8\u4e5f\u8d0a\u52a9\u591a\u9805\u8f49\u79fb\u6027\u4e73\u764c\u7684\u81e8\u5e8a\u8a66\u9a57\uff0c\u63a2\u8a0e elacestrant \u55ae\u7368\u6216\u7d50\u5408\u5176\u4ed6\u7642\u6cd5\u7684\u6cbb\u7642\u3002ELEVATE (NCT05563220) \u662f\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 alpelisib\u3001everolimus\u3001capivasertib\u3001palbociclib\u3001ribociclib \u6216 abemaciclib \u7684\u5b89\u5168\u8207\u7642\u6548\u3002ELECTRA (NCT05386108) \u662f\u7b2c 1b\/2 \u671f\u3001\u958b\u653e\u6a19\u7c64\u517c\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 abemaciclib \u670d\u7528\uff0c\u5c0d ER+ \u548c HER2- \u4e73\u764c\u60a3\u8005\u7684\u6548\u679c\u3002\u7b2c 2 \u968e\u6bb5\u5247\u8a55\u4f30\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6cbb\u7642\u65b9\u6848\u3002ELCIN (NCT05596409) \u662f\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u5c0d ER+ \u548c HER2- \u665a\u671f\/\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\u3002\u9019\u4e9b\u60a3\u8005\u66fe\u63a5\u53d7\u4e00\u81f3\u5169\u7a2e\u8377\u723e\u8499\u7642\u6cd5\uff0c\u4f46\u5728\u8f49\u79fb\u6027\u60c5\u6cc1\u4e2d\uff0c\u672a\u66fe\u670d\u7528 CDK4\/6 \u6291\u5236\u5291\u3002ADELA (NCT06382948) \u662f\u7b2c 3 \u671f\u3001\u96a8\u6a5f\u517c\u96d9\u76f2\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 everolimus \u6cbb\u7642 ER+ \u548c HER2- mBC \u53ca ESR1-mut \u816b\u7624\u60a3\u8005\u7684\u7642\u6548\u3002Elacestrant \u4e5f\u65bc\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\uff0c\u70ba\u8f49\u79fb\u6027\u4e73\u764c\u548c\u65e9\u671f\u75be\u75c5\u9032\u884c\u8a55\u4f30\u3002 \u95dc\u65bc ORSERDU (elacestrant)\u5728\u7f8e\u570b\u6838\u51c6\u7684\u9069\u61c9\u75c7\uff1aORSERDU (elacestrant) \u662f 345 \u6beb\u514b\u7247\u5291\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u6216\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ESR1) \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u517c\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u65bc\u63a5\u53d7\u81f3\u5c11\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u9032\u5c55\u3002 \u5982\u6b32\u4e86\u89e3\u7f8e\u570b\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u6599\uff0c\u8acb\u700f\u89bd www.orserdu.com\u3002 \u91cd\u8981\u5b89\u5168\u8cc7\u8a0a\u8b66\u544a\u548c\u6ce8\u610f\u4e8b\u9805 \u9ad8\u8102\u8840\u75c7\uff1a\u670d\u7528 ORSERDU \u7684\u60a3\u8005\u4e2d\uff0c\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 30% \u548c 27%\u3002\u7b2c 3 \u7d1a\u548c\u7b2c 4 \u7d1a\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 0.9% \u548c 2.2%\u3002\u958b\u59cb\u670d\u7528 ORSERDU \u524d\u548c\u670d\u7528\u671f\u9593\uff0c\u5b9a\u671f\u76e3\u6e2c\u8840\u8102\u72c0\u6cc1\u3002 \u80da\u80ce-\u80ce\u5152\u6bd2\u6027\uff1a\u6839\u64da\u52d5\u7269\u5be6\u9a57\u7d50\u679c\u53ca\u7576\u4e2d\u4f5c\u7528\u6a5f\u5236\uff0c\u5b55\u5a66\u670d\u7528 ORSERDU\uff0c\u53ef\u80fd\u5c0d\u80ce\u5152\u9020\u6210\u50b7\u5bb3\u3002\u8acb\u544a\u77e5\u5b55\u5a66\u548c\u80b2\u9f61\u5973\u6027\uff0c\u80ce\u5152\u53ef\u80fd\u9762\u5c0d\u7684\u98a8\u96aa\u3002\u5efa\u8b70\u80b2\u9f61\u5973\u6027\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u548c\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002\u5efa\u8b70\u6709\u751f\u80b2\u80fd\u529b\u5973\u6027\u4f34\u4fb6\u7684\u7537\u6027\u60a3\u8005\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002 \u4e0d\u826f\u53cd\u61c9 12% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\uff0c\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\u3002\u5728\u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0c\u8d85\u904e 1% \u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u808c\u8089\u9aa8\u9abc\u75bc\u75db (1.7%) \u548c\u5641\u5fc3 (1.3%)\u30021.7% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u51fa\u73fe\u81f4\u547d\u7684\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u5fc3\u81df\u9a5f\u505c\u3001\u6557\u8840\u6027\u4f11\u514b\u3001\u61a9\u5ba4\u708e\u548c\u539f\u56e0\u4e0d\u660e\u7684\u60c5\u6cc1\uff08\u5404\u4e00\u4f8b\uff09\u3002ORSERDU \u6700\u5e38\u898b\u7684\u4e0d\u826f\u53cd\u61c9 (&gt; 10%)\uff0c\u5305\u62ec\u5be6\u9a57\u5ba4\u7570\u5e38\uff0c\u662f\u808c\u8089\u9aa8\u9abc\u75bc\u75db (41%)\u3001\u5641\u5fc3 (35%)\u3001\u81bd\u56fa\u9187\u5347\u9ad8 (30%)\u3001AST \u589e\u52a0 (29%)\u3001\u7518\u6cb9\u4e09\u916f\u589e\u52a0 (27%)\u3001\u75b2\u52de (26%)\u3001\u8840\u7d05\u86cb\u767d\u4e0b\u964d (26%)\u3001\u5614\u5410 (19%)\u3001ALT \u589e\u9ad8 (17%)\u3001\u9209\u964d\u4f4e (16%)\u3001\u808c\u9178\u589e\u52a0 (16%)\u3001\u98df\u617e\u4e0b\u964d (15%)\u3001\u8179\u7009 (13%)\u3001\u982d\u75db (12%)\u3001\u4fbf\u79d8 (12%)\u3001\u8179\u75db (11%)\u3001\u6f6e\u71b1 (11%) \u548c\u6d88\u5316\u4e0d\u826f (10%)\u3002 \u85e5\u7269\u4ea4\u4e92\u53cd\u61c9 \u540c\u6642\u670d\u7528 CYP3A4 \u8a98\u5c0e\u5291\u548c\/\u6216\u6291\u5236\u5291\uff1a\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u6291\u5236\u5291\u548c ORSERDU\u3002\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u8a98\u5c0e\u5291\u548c ORSERDU\u3002 \u7279\u5b9a\u4eba\u58eb\u670d\u7528\u9808\u77e5 \u54fa\u4e73\u671f\uff1a\u5efa\u8b70\u54fa\u4e73\u5a66\u5973\u670d\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u5207\u52ff\u54fa\u4e73\u3002\u809d\u529f\u80fd\u53d7\u640d\uff1a\u5207\u52ff\u4e88\u56b4\u91cd\u809d\u529f\u80fd\u4e0d\u5168 (Child-Pugh C) \u7684\u60a3\u8005\u670d\u7528 ORSERDU\u3002\u5c0d\u65bc\u4e2d\u5ea6\u809d\u529f\u80fd\u4e0d\u5168\uff08Child-Pugh B\uff09\u7684\u60a3\u8005\uff0c\u61c9\u964d\u4f4e ORSERDU \u7684\u5291\u91cf\u3002\u5c1a\u672a\u78ba\u5b9a ORSERDU \u5c0d\u5152\u79d1\u60a3\u8005\u7684\u5b89\u5168\u548c\u6210\u6548\u3002 \u5982\u6b32\u5831\u544a\u61f7\u7591\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff08\u96fb\u8a71\uff1a1-877-332-7961\uff09\u6216\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\uff08\u96fb\u8a71\uff1a1-800-FDA-1088 \u6216\u7db2\u4e0a\u7559\u8a00\uff1awww.fda.gov\/medwatch\uff09\u3002 \u95dc\u65bc Menarini Group Menarini Group \u662f\u570b\u969b\u9818\u5148\u7684\u88fd\u85e5\u548c\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u9054 50 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u8d85\u904e 17,000 \u540d\u3002Menarini \u5c08\u6ce8\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u75c5\u5b78\u3001\u816b\u7624\u5b78\u3001\u80ba\u75c5\u5b78\u3001\u80c3\u8178\u75c5\u5b78\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u5b78\u3001\u767c\u708e\u548c\u93ae\u75db\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u904d\u4f48\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 Stemline Therapeutics Inc. \u7c21\u4ecbMenarini Group \u5168\u8cc7\u5b50\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u662f\u4e00\u9593\u5546\u696d\u968e\u6bb5\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u70ba\u75c5\u4eba\u63d0\u4f9b\u5d84\u65b0\u816b\u7624\u6cbb\u7642\u3002Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316 elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u7684\u5df2\u505c\u7d93\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u63a5\u53d7\u6700\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u7642\u6cd5\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u60e1\u5316\u3002Stemline \u4e5f\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269 tagraxofusp-erzs\u3002\u9019\u85e5\u7269\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u72c0\u7d30\u80de\u816b\u7624 (BPDCN)\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002\u6b64\u5916\uff0cStemline \u65bc\u6b50\u6d32\u5546\u696d\u5316 selinexor\uff0c\u9019\u662f\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1\u6291\u5236\u5291\u3002\u8a72\u516c\u53f8\u9084\u5c31\u4e73\u764c\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u9069\u61c9\u75c7\uff0c\u5206\u5225\u5229\u7528 elacestrant \u548c tagraxofusp \u4f5c\u591a\u9805\u6a19\u7c64\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u70ba\u5be6\u9ad4\u764c\u75c7\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u75c5\u4eba\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\uff0c\u64c1\u6709\u8655\u65bc\u4e0d\u540c\u7814\u767c\u968e\u6bb5\u7684\u5ee3\u6cdb\u81e8\u5e8a\u7ba1\u7dda\u3002  Lloyd\u00a0et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3033\/768341\/Clinical-and-Genomic-Factors-Associated-with  Rugo et al.\u00a0Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. \u00a0Clin Cancer Res, 2025. CCR-25-3040R1.\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3040\/768340\/Real-World-Outcomes-of-Elacestrant-in-ER-HER2-ESR1","og_url":"https:\/\/pingtungtimes.com.tw\/?p=391065","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2025-12-09T19:24:00+00:00","og_image":[{"width":1706,"height":960,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"2 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=391065#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=391065"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da","datePublished":"2025-12-09T19:24:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=391065"},"wordCount":374,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=391065#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2025\/12\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=391065","url":"https:\/\/pingtungtimes.com.tw\/?p=391065","name":"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=391065#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=391065#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2025\/12\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg","datePublished":"2025-12-09T19:24:00+00:00","description":"\u6b64\u5916\uff0celacestrant \u5ee3\u6cdb\u7684\u81e8\u5e8a\u958b\u767c\u8a08\u5283\u6700\u65b0\u9032\u5c55\uff0c\u9032\u4e00\u6b65\u978f\u56fa\u5176\u4f5c\u70ba\u806f\u5408\u6cbb\u7642\u3001\u4ee5\u53ca\u8f49\u79fb\u6027\u548c\u65e9\u671f\u4e73\u764c\u6cbb\u7642\u4e2d\u9aa8\u5e79\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u6f5b\u529b\u3002 \u610f\u5927\u5229\u4f5b\u7f85\u502b\u65af\u53ca\u7d10\u7d042025\u5e7412\u670810\u65e5 \/\u7f8e\u901a\u793e\/ -- \u570b\u969b\u9818\u5148\u7684\u85e5\u696d\u53ca\u8a3a\u65b7\u516c\u53f8 Menarini Group\uff08\u4e0b\u7a31\u300cMenarini\u300d\uff09\uff0c\u8207\u5176\u5c08\u6ce8\u65bc\u70ba\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u8b8a\u9769\u6027\u816b\u7624\u7642\u6cd5\u7684\u5168\u8cc7\u9644\u5c6c\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u4e0b\u7a31\u300cStemline\u300d\uff09\uff0c\u5ba3\u4f48\u5c07\u516c\u4f48\u7b2c 2 \u671f ELEVATE \u7814\u7a76\u4e2d\u5169\u9805\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u6700\u65b0\u5177\u81e8\u5e8a\u610f\u7fa9\u7684\u4e2d\u4f4d\u7121\u60e1\u5316\u5b58\u6d3b\u671f (mPFS) \u7642\u6548\u7d50\u679c\uff0c\u8a72\u7814\u7a76\u91dd\u5c0d\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u7684\u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u3002ELEVATE \u7814\u7a76\u65e8\u5728\u8a55\u4f30\u5168\u53e3\u670d\u806f\u5408\u6cbb\u7642\u65b9\u6848\u7684\u5b89\u5168\u6027\u53ca\u7642\u6548\uff0c\u85c9\u4ee5\u514b\u670d ER+\/HER2- mBC \u4e2d\u89c0\u5bdf\u5230\u7684\u4e0d\u540c\u6297\u85e5\u6a5f\u5236\uff0c\u5f9e\u800c\u6539\u5584\u60a3\u8005\u7684\u6cbb\u7642\u6210\u6548\u3002\u76f8\u95dc\u6578\u64da\u5c07\u65bc 12 \u6708 9 \u65e5\u81f3 12 \u65e5\u8209\u884c\u7684 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703 (SABCS) \u4e0a\u767c\u8868\u3002 \u300c\u4ee4\u4eba\u9f13\u821e\u7684\u7121\u60e1\u5316\u5b58\u6d3b\u671f\u6578\u64da\uff0c\u589e\u5f37\u4e86\u6211\u5011\u5c0d elacestrant \u5728\u806f\u5408\u6cbb\u7642\u4e2d\u4f5c\u70ba\u5167\u5206\u6ccc\u6cbb\u7642\u9aa8\u5e79\u89d2\u8272\u7684\u4fe1\u5fc3\u3002\u300d\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821\u5065\u5eb7\u79d1\u5b78\u4e2d\u5fc3\u8840\u6db2\u5b78\/\u816b\u7624\u79d1\u91ab\u5b78\u6559\u6388\u517c\u5fb7\u5dde\u5927\u5b78\u8056\u5b89\u6771\u5c3c\u5967\u5206\u6821 MD \u5b89\u5fb7\u68ee\u764c\u75c7\u4e2d\u5fc3\u4e73\u764c\u9805\u76ee\u8ca0\u8cac\u4eba Virginia Kaklamani \u91ab\u5b78\u535a\u58eb\u8868\u793a\uff0c\u00a0\u300cElacestrant \u8207 everolimus \u6216 abemaciclib \u806f\u5408\u4f7f\u7528\u7684\u5b89\u5168\u6027\u7279\u5fb5\uff0c\u8207\u6bcf\u7a2e\u85e5\u7269\u5df2\u77e5\u7684\u5b89\u5168\u6027\u7279\u5fb5\u4e00\u81f4\u3002\u4e26\u672a\u767c\u73fe\u65b0\u7684\u5b89\u5168\u8a0a\u865f\u3002\u300d \u5c07\u65bc SABCS \u767c\u8868\u7684 ELEVATE \u6578\u64da\u986f\u793a\uff0c\u5c0d\u65bc\u66fe\u5728\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5f8c\u75c5\u60c5\u60e1\u5316\uff08\u4e0d\u8ad6\u662f\u5426\u66fe\u4f7f\u7528 CDK4\/6 \u6291\u5236\u5291\uff09\u7684 ER+\/HER2- mBC \u60a3\u8005\uff0celacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u5747\u986f\u793a\u51fa\u4e00\u81f4\u7684 PFS \u6548\u76ca\uff0c\u4e14\u4e0d\u53d7 ESR1 \u7a81\u8b8a\u72c0\u614b\u5f71\u97ff\u3002\u6700\u65b0\u7d50\u679c\u4ea6\u986f\u793a\uff0c\u806f\u5408\u7642\u6cd5\u7684\u5b89\u5168\u6027\u8207\u5404\u6a19\u9776\u7642\u6cd5\u52a0\u4e0a\u6a19\u6e96\u8b77\u7406\u5167\u5206\u6ccc\u7642\u6cd5\u7684\u5df2\u77e5\u5b89\u5168\u6027\u4e00\u81f4\u3002 \u7b2c 2 \u671f mPFS\uff08\u6708\uff09\uff0895% \u7f6e\u4fe1\u5340\u9593 \uff09\uff0c\u6db5\u84cb\u6240\u6709\u60a3\u8005\u53ca\u4e9e\u7d44 \u60a3\u8005\u7fa4\u9ad4 Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Everolimus 7.5mg \u6bcf\u65e5\u4e00\u6b21 (n = 50) Elacestrant 345 mg \u6bcf\u65e5\u4e00\u6b21 + Abemaciclib 150 mg \u6bcf\u65e5\u5169\u6b21 (n = 60) \u6240\u6709\u60a3\u8005 8.3 14.3 \u5167\u81df\u8f49\u79fb 7.7 14.3 \u672a\u66fe\u63a5\u53d7 fulvestrant \u6cbb\u7642 8.3 14.8 \u7121\u539f\u767c\u6027\u5167\u5206\u6ccc\u6297\u85e5\u6027 8.3 14.3 ESR1\u7a81\u8b8a 8.7 * ESR1\u91ce\u751f\u578b 9.0 * PIK3CA\u7a81\u8b8a 8.3 * PIK3CA\u91ce\u751f\u578b 9.6 * *Elacestrant + abemaciclib \u968a\u5217\u4e2d\u7684\u57fa\u56e0\u7d44\u4e9e\u7d44 (ESR1 \/ PIK3CA) \u4e4b PFS \u5c1a\u672a\u6210\u719f (95% CI)\u3002 \u00a0 \u300cElacestrant \u64c1\u6709\u5ee3\u6cdb\u7684\u8b49\u64da\u652f\u6301\uff0c\u6db5\u84cb\u4e86\u6211\u5011\u95dc\u9375 EMERALD \u7814\u7a76\u4e2d\u7684\u55ae\u85e5\u6cbb\u7642\u8a2d\u5b9a\uff08\u73fe\u66f4\u6709\u5169\u4efd\u8fd1\u671f\u767c\u8868\u7684\u771f\u5be6\u4e16\u754c\u6578\u64da\u6587\u737b\u652f\u6301, \uff09\uff0c\u4ee5\u53ca\u5982 SABCS \u767c\u8868\u6578\u64da\u6240\u5f37\u8abf\uff0c\u5176\u5728\u806f\u5408\u6cbb\u7642\u65b9\u6848\u4e2d\u65e5\u76ca\u589e\u9577\u7684\u6f5b\u529b\u3002\u300dMenarini Group \u884c\u653f\u7e3d\u88c1 Elcin Barker Ergun \u8868\u793a\uff0c\u300c\u6211\u5011\u81f4\u529b\u900f\u904e\u591a\u9805\u91dd\u5c0d\u65e9\u671f\u53ca\u8f49\u79fb\u6027\u4e73\u764c\u7684\u9032\u884c\u4e2d\u8a66\u9a57\uff0c\u5168\u9762\u63a2\u7d22 elacestrant \u7684\u6f5b\u5728\u6548\u76ca\u3002\u300d \u6b64\u5916\uff0c\u5176\u4ed6 elacestrant \u7684\u66f4\u65b0\u8cc7\u8a0a\u4ea6\u5c07\u65bc SABCS \u767c\u8868\uff0c\u63a2\u8a0e\u5176\u5728\u5404\u985e\u4e73\u764c\u6cbb\u7642\u4e2d\u7684\u6f5b\u529b\uff1a \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u806f\u5408 everolimus \u6216 abemaciclib \u6cbb\u7642 ER+\/HER2- \u5c40\u90e8\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\uff1aELEVATE \u958b\u653e\u6a19\u7c64\u5098\u5f0f\u7814\u7a76\u7684\u7b2c 2 \u671f\u7d50\u679c\u6458\u8981\u7de8\u865f\uff1a1255\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 1:00 \u2013 2:00\u5730\u9ede\uff1aHemisfair 1-2 \u767c\u8868\u6f14\u8b1b\u8005\uff1a Hope S. Rugo \u7c21\u5831\u984c\u76ee\uff1aElacestrant \u55ae\u85e5\u6216\u806f\u5408 triptorelin \u6cbb\u7642 ER+\/HER2- \u65e9\u671f\u4e73\u764c\u7d55\u7d93\u524d\u5973\u6027\uff1aSOLTI-2104-Premi\u00c8Re \u7b2c 2 \u671f\u8a66\u9a57\u7684\u4e3b\u8981\u5206\u6790\u6458\u8981\u7de8\u865f\uff1a1123\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0a\u5348 7:30 \u2013 7:33\u5730\u9ede\uff1a301 ABC\u767c\u8868\u6f14\u8b1b\u8005\uff1aMertixell Bellet \u7c21\u5831\u984c\u76ee\uff1aELEGANT\uff1a\u4e00\u9805\u5728\u5168\u7403\u591a\u4e2d\u5fc3\u9032\u884c\u7684\u96a8\u6a5f\u3001\u958b\u653e\u6a19\u7c64\u7b2c 3 \u671f\u7814\u7a76\uff0c\u6bd4\u8f03 Elacestrant \u8207\u6a19\u6e96\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u5728\u6dcb\u5df4\u7d50\u967d\u6027\u3001\u96cc\u6fc0\u7d20\u53d7\u9ad4\u967d\u6027 (ER+)\u3001HER2 \u9670\u6027 (HER2-) \u4e14\u5177\u9ad8\u5fa9\u767c\u98a8\u96aa\u7684\u65e9\u671f\u4e73\u764c (eBC) \u5973\u6027\u53ca\u7537\u6027\u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1276\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 11 \u65e5\uff08\u661f\u671f\u56db\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAditya Bardia \u7c21\u5831\u984c\u76ee\uff1a ADELA \u7814\u7a76\uff1a\u4e00\u9805\u96d9\u76f2\u3001\u5b89\u6170\u5291\u5c0d\u7167\u3001\u96a8\u6a5f\u7b2c 3 \u671f\u8a66\u9a57\uff0c\u6bd4\u8f03 Elacestrant (ELA) + Everolimus (EVE) \u5c0d\u6bd4 ELA + \u5b89\u6170\u5291 (PBO) \u5728\u66fe\u63a5\u53d7\u5167\u5206\u6ccc\u6cbb\u7642 (ET) \u53ca CDK4\/6 \u6291\u5236\u5291\u5f8c\u75c5\u60c5\u60e1\u5316\u4e14\u5e36\u6709 ESR1 \u7a81\u8b8a\u816b\u7624\u7684 ER+\/HER2- \u665a\u671f\u4e73\u764c (aBC) \u60a3\u8005\u4e2d\u7684\u7642\u6548\u3002\u6458\u8981\u7de8\u865f\uff1a1141\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 10 \u65e5\uff08\u661f\u671f\u4e09\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aAntonio Llombart-Cussac \u7c21\u5831\u984c\u76ee\uff1aERADICATE\uff1a\u4e00\u9805\u7b2c Ib\/II \u671f\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u806f\u5408 trastuzumab deruxtecan \u6cbb\u7642\u5c0d CDK4\/6 \u6291\u5236\u5291\u53ca\u5167\u5206\u6ccc\u6cbb\u7642\u7522\u751f\u6297\u85e5\u6027\u7684 HR+\/HER2-\u4f4e\u8868\u9054 (low) \u6216 HER2-\u8d85\u4f4e\u8868\u9054 (ultralow) \u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u3002\u6458\u8981\u7de8\u865f\uff1a2119\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1a Henry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aSara L. Sammons \u7c21\u5831\u984c\u76ee\uff1a\u8853\u524d\u63a5\u53d7 Elacestrant \u53ca PULSAR \u81ea\u9069\u61c9\u653e\u5c04\u6cbb\u7642\u7684\u8377\u723e\u8499\u53d7\u9ad4 (HR) \u967d\u6027 HER2 \u9670\u6027\u4e73\u764c\u60a3\u8005\uff1a\u4e00\u9805\u7b2c II \u671f\u7814\u7a76 (HELP \u8a66\u9a57) \u6458\u8981\u7de8\u865f\uff1a1071\u767c\u8868\u65e5\u671f\u53ca\u6642\u9593\uff1a2025 \u5e74 12 \u6708 12 \u65e5\uff08\u661f\u671f\u4e94\uff09\uff0c\u4e0b\u5348 12:30 \u2013 2:00\u5730\u9ede\uff1aHenry B. Convention Center\u767c\u8868\u6f14\u8b1b\u8005\uff1aLuca Visani \u95dc\u65bc Elacestrant Clinical Development Program \u6b64\u5916\uff0c\u8a72\u516c\u53f8\u4e5f\u8d0a\u52a9\u591a\u9805\u8f49\u79fb\u6027\u4e73\u764c\u7684\u81e8\u5e8a\u8a66\u9a57\uff0c\u63a2\u8a0e elacestrant \u55ae\u7368\u6216\u7d50\u5408\u5176\u4ed6\u7642\u6cd5\u7684\u6cbb\u7642\u3002ELEVATE (NCT05563220) \u662f\u7b2c 1b\/2 \u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 alpelisib\u3001everolimus\u3001capivasertib\u3001palbociclib\u3001ribociclib \u6216 abemaciclib \u7684\u5b89\u5168\u8207\u7642\u6548\u3002ELECTRA (NCT05386108) \u662f\u7b2c 1b\/2 \u671f\u3001\u958b\u653e\u6a19\u7c64\u517c\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 abemaciclib \u670d\u7528\uff0c\u5c0d ER+ \u548c HER2- \u4e73\u764c\u60a3\u8005\u7684\u6548\u679c\u3002\u7b2c 2 \u968e\u6bb5\u5247\u8a55\u4f30\u8166\u8f49\u79fb\u60a3\u8005\u7684\u6cbb\u7642\u65b9\u6848\u3002ELCIN (NCT05596409) \u662f\u7b2c 2 \u671f\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u5c0d ER+ \u548c HER2- \u665a\u671f\/\u8f49\u79fb\u6027\u4e73\u764c\u60a3\u8005\u7684\u7642\u6548\u3002\u9019\u4e9b\u60a3\u8005\u66fe\u63a5\u53d7\u4e00\u81f3\u5169\u7a2e\u8377\u723e\u8499\u7642\u6cd5\uff0c\u4f46\u5728\u8f49\u79fb\u6027\u60c5\u6cc1\u4e2d\uff0c\u672a\u66fe\u670d\u7528 CDK4\/6 \u6291\u5236\u5291\u3002ADELA (NCT06382948) \u662f\u7b2c 3 \u671f\u3001\u96a8\u6a5f\u517c\u96d9\u76f2\u8a66\u9a57\uff0c\u8a55\u4f30 elacestrant \u7d50\u5408 everolimus \u6cbb\u7642 ER+ \u548c HER2- mBC \u53ca ESR1-mut \u816b\u7624\u60a3\u8005\u7684\u7642\u6548\u3002Elacestrant \u4e5f\u65bc\u5176\u4ed6\u7531\u7814\u7a76\u8005\u4e3b\u5c0e\u7684\u8a66\u9a57\uff0c\u4ee5\u53ca\u8207\u5176\u4ed6\u516c\u53f8\u5408\u4f5c\u9032\u884c\u7684\u8a66\u9a57\u4e2d\uff0c\u70ba\u8f49\u79fb\u6027\u4e73\u764c\u548c\u65e9\u671f\u75be\u75c5\u9032\u884c\u8a55\u4f30\u3002 \u95dc\u65bc ORSERDU (elacestrant)\u5728\u7f8e\u570b\u6838\u51c6\u7684\u9069\u61c9\u75c7\uff1aORSERDU (elacestrant) \u662f 345 \u6beb\u514b\u7247\u5291\uff0c\u9069\u7528\u65bc\u6cbb\u7642\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u6216\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ESR1) \u7a81\u8b8a\u7684\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u517c\u505c\u7d93\u5f8c\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u65bc\u63a5\u53d7\u81f3\u5c11\u4e00\u7dda\u5167\u5206\u6ccc\u6cbb\u7642\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u9032\u5c55\u3002 \u5982\u6b32\u4e86\u89e3\u7f8e\u570b\u7684\u5b8c\u6574\u8655\u65b9\u8cc7\u6599\uff0c\u8acb\u700f\u89bd www.orserdu.com\u3002 \u91cd\u8981\u5b89\u5168\u8cc7\u8a0a\u8b66\u544a\u548c\u6ce8\u610f\u4e8b\u9805 \u9ad8\u8102\u8840\u75c7\uff1a\u670d\u7528 ORSERDU \u7684\u60a3\u8005\u4e2d\uff0c\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 30% \u548c 27%\u3002\u7b2c 3 \u7d1a\u548c\u7b2c 4 \u7d1a\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u548c\u9ad8\u4e09\u9178\u7518\u6cb9\u8102\u8840\u75c7\u7684\u767c\u751f\u7387\u5206\u5225\u70ba 0.9% \u548c 2.2%\u3002\u958b\u59cb\u670d\u7528 ORSERDU \u524d\u548c\u670d\u7528\u671f\u9593\uff0c\u5b9a\u671f\u76e3\u6e2c\u8840\u8102\u72c0\u6cc1\u3002 \u80da\u80ce-\u80ce\u5152\u6bd2\u6027\uff1a\u6839\u64da\u52d5\u7269\u5be6\u9a57\u7d50\u679c\u53ca\u7576\u4e2d\u4f5c\u7528\u6a5f\u5236\uff0c\u5b55\u5a66\u670d\u7528 ORSERDU\uff0c\u53ef\u80fd\u5c0d\u80ce\u5152\u9020\u6210\u50b7\u5bb3\u3002\u8acb\u544a\u77e5\u5b55\u5a66\u548c\u80b2\u9f61\u5973\u6027\uff0c\u80ce\u5152\u53ef\u80fd\u9762\u5c0d\u7684\u98a8\u96aa\u3002\u5efa\u8b70\u80b2\u9f61\u5973\u6027\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u548c\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002\u5efa\u8b70\u6709\u751f\u80b2\u80fd\u529b\u5973\u6027\u4f34\u4fb6\u7684\u7537\u6027\u60a3\u8005\u4f7f\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u63a1\u53d6\u6709\u6548\u907f\u5b55\u63aa\u65bd\u3002 \u4e0d\u826f\u53cd\u61c9 12% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\uff0c\u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\u3002\u5728\u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u4e2d\uff0c\u8d85\u904e 1% \u51fa\u73fe\u56b4\u91cd\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u808c\u8089\u9aa8\u9abc\u75bc\u75db (1.7%) \u548c\u5641\u5fc3 (1.3%)\u30021.7% \u63a5\u53d7 ORSERDU \u6cbb\u7642\u7684\u60a3\u8005\u51fa\u73fe\u81f4\u547d\u7684\u4e0d\u826f\u53cd\u61c9\uff0c\u5305\u62ec\u5fc3\u81df\u9a5f\u505c\u3001\u6557\u8840\u6027\u4f11\u514b\u3001\u61a9\u5ba4\u708e\u548c\u539f\u56e0\u4e0d\u660e\u7684\u60c5\u6cc1\uff08\u5404\u4e00\u4f8b\uff09\u3002ORSERDU \u6700\u5e38\u898b\u7684\u4e0d\u826f\u53cd\u61c9 (&gt; 10%)\uff0c\u5305\u62ec\u5be6\u9a57\u5ba4\u7570\u5e38\uff0c\u662f\u808c\u8089\u9aa8\u9abc\u75bc\u75db (41%)\u3001\u5641\u5fc3 (35%)\u3001\u81bd\u56fa\u9187\u5347\u9ad8 (30%)\u3001AST \u589e\u52a0 (29%)\u3001\u7518\u6cb9\u4e09\u916f\u589e\u52a0 (27%)\u3001\u75b2\u52de (26%)\u3001\u8840\u7d05\u86cb\u767d\u4e0b\u964d (26%)\u3001\u5614\u5410 (19%)\u3001ALT \u589e\u9ad8 (17%)\u3001\u9209\u964d\u4f4e (16%)\u3001\u808c\u9178\u589e\u52a0 (16%)\u3001\u98df\u617e\u4e0b\u964d (15%)\u3001\u8179\u7009 (13%)\u3001\u982d\u75db (12%)\u3001\u4fbf\u79d8 (12%)\u3001\u8179\u75db (11%)\u3001\u6f6e\u71b1 (11%) \u548c\u6d88\u5316\u4e0d\u826f (10%)\u3002 \u85e5\u7269\u4ea4\u4e92\u53cd\u61c9 \u540c\u6642\u670d\u7528 CYP3A4 \u8a98\u5c0e\u5291\u548c\/\u6216\u6291\u5236\u5291\uff1a\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u6291\u5236\u5291\u548c ORSERDU\u3002\u5207\u52ff\u540c\u6642\u670d\u7528\u5f37\u6548\u6216\u4e2d\u6548 CYP3A4 \u8a98\u5c0e\u5291\u548c ORSERDU\u3002 \u7279\u5b9a\u4eba\u58eb\u670d\u7528\u9808\u77e5 \u54fa\u4e73\u671f\uff1a\u5efa\u8b70\u54fa\u4e73\u5a66\u5973\u670d\u7528 ORSERDU \u6cbb\u7642\u671f\u9593\u53ca\u6700\u5f8c\u4e00\u6b21\u670d\u85e5\u5f8c 1 \u9031\u5167\uff0c\u5207\u52ff\u54fa\u4e73\u3002\u809d\u529f\u80fd\u53d7\u640d\uff1a\u5207\u52ff\u4e88\u56b4\u91cd\u809d\u529f\u80fd\u4e0d\u5168 (Child-Pugh C) \u7684\u60a3\u8005\u670d\u7528 ORSERDU\u3002\u5c0d\u65bc\u4e2d\u5ea6\u809d\u529f\u80fd\u4e0d\u5168\uff08Child-Pugh B\uff09\u7684\u60a3\u8005\uff0c\u61c9\u964d\u4f4e ORSERDU \u7684\u5291\u91cf\u3002\u5c1a\u672a\u78ba\u5b9a ORSERDU \u5c0d\u5152\u79d1\u60a3\u8005\u7684\u5b89\u5168\u548c\u6210\u6548\u3002 \u5982\u6b32\u5831\u544a\u61f7\u7591\u4e0d\u826f\u53cd\u61c9\uff0c\u8acb\u806f\u7d61 Stemline Therapeutics, Inc.\uff08\u96fb\u8a71\uff1a1-877-332-7961\uff09\u6216\u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (FDA)\uff08\u96fb\u8a71\uff1a1-800-FDA-1088 \u6216\u7db2\u4e0a\u7559\u8a00\uff1awww.fda.gov\/medwatch\uff09\u3002 \u95dc\u65bc Menarini Group Menarini Group \u662f\u570b\u969b\u9818\u5148\u7684\u88fd\u85e5\u548c\u8a3a\u65b7\u516c\u53f8\uff0c\u71df\u696d\u984d\u9054 50 \u5104\u7f8e\u5143\uff0c\u54e1\u5de5\u8d85\u904e 17,000 \u540d\u3002Menarini \u5c08\u6ce8\u5c1a\u672a\u6eff\u8db3\u517c\u5927\u91cf\u9700\u6c42\u7684\u6cbb\u7642\u9818\u57df\uff0c\u7522\u54c1\u6db5\u84cb\u5fc3\u81df\u75c5\u5b78\u3001\u816b\u7624\u5b78\u3001\u80ba\u75c5\u5b78\u3001\u80c3\u8178\u75c5\u5b78\u3001\u50b3\u67d3\u75c5\u3001\u7cd6\u5c3f\u75c5\u5b78\u3001\u767c\u708e\u548c\u93ae\u75db\u9818\u57df\u3002Menarini \u64c1\u6709 18 \u500b\u751f\u7522\u57fa\u5730\u53ca 9 \u500b\u7814\u767c\u4e2d\u5fc3\uff0c\u7522\u54c1\u904d\u4f48\u5168\u7403 140 \u500b\u570b\u5bb6\/\u5730\u5340\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u76f8\u95dc\u8cc7\u8a0a\uff0c\u8acb\u700f\u89bd www.menarini.com\u3002 Stemline Therapeutics Inc. \u7c21\u4ecbMenarini Group \u5168\u8cc7\u5b50\u516c\u53f8 Stemline Therapeutics, Inc.\uff08\u300cStemline\u300d\uff09\u662f\u4e00\u9593\u5546\u696d\u968e\u6bb5\u751f\u7269\u88fd\u85e5\u516c\u53f8\uff0c\u5c08\u6ce8\u70ba\u75c5\u4eba\u63d0\u4f9b\u5d84\u65b0\u816b\u7624\u6cbb\u7642\u3002Stemline \u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316 elacestrant\u3002\u9019\u662f\u4e00\u7a2e\u53e3\u670d\u5167\u5206\u6ccc\u85e5\u7269\uff0c\u7528\u65bc\u6cbb\u7642\u96cc\u6fc0\u7d20\u53d7\u9ad4 (ER) \u967d\u6027\u3001\u7b2c\u4e8c\u578b\u4eba\u985e\u8868\u76ae\u751f\u9577\u56e0\u5b50\u53d7\u9ad4 (HER2) \u9670\u6027\u3001ESR1 \u7a81\u8b8a\u665a\u671f\u6216\u8f49\u79fb\u6027\u4e73\u764c\u7684\u5df2\u505c\u7d93\u5973\u6027\u6216\u6210\u5e74\u7537\u6027\uff0c\u4e26\u63a5\u53d7\u6700\u5c11\u4e00\u7a2e\u5167\u5206\u6ccc\u7642\u6cd5\u5f8c\uff0c\u75c5\u60c5\u51fa\u73fe\u60e1\u5316\u3002Stemline \u4e5f\u65bc\u7f8e\u570b\u3001\u6b50\u6d32\u548c\u5168\u7403\u5176\u4ed6\u5730\u5340\uff0c\u5546\u696d\u5316\u91dd\u5c0d CD123 \u7684\u65b0\u578b\u6a19\u9776\u85e5\u7269 tagraxofusp-erzs\u3002\u9019\u85e5\u7269\u7528\u65bc\u6cbb\u7642\u6bcd\u7d30\u80de\u6027\u6f3f\u7d30\u80de\u6a23\u6a39\u7a81\u72c0\u7d30\u80de\u816b\u7624 (BPDCN)\uff0c\u5373\u4fb5\u8972\u6027\u8840\u6db2\u764c\u75c7\u3002\u6b64\u5916\uff0cStemline \u65bc\u6b50\u6d32\u5546\u696d\u5316 selinexor\uff0c\u9019\u662f\u6cbb\u7642\u591a\u767c\u6027\u9aa8\u9ad3\u7624\u7684 XPO1\u6291\u5236\u5291\u3002\u8a72\u516c\u53f8\u9084\u5c31\u4e73\u764c\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u9069\u61c9\u75c7\uff0c\u5206\u5225\u5229\u7528 elacestrant \u548c tagraxofusp \u4f5c\u591a\u9805\u6a19\u7c64\u64f4\u5c55\u7814\u7a76\uff0c\u4e26\u70ba\u5be6\u9ad4\u764c\u75c7\u548c\u8840\u6db2\u7cfb\u7d71\u764c\u75c7\u75c5\u4eba\u7684\u5176\u4ed6\u5019\u9078\u85e5\u7269\uff0c\u64c1\u6709\u8655\u65bc\u4e0d\u540c\u7814\u767c\u968e\u6bb5\u7684\u5ee3\u6cdb\u81e8\u5e8a\u7ba1\u7dda\u3002 Lloyd\u00a0et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res (2025).\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3033\/768341\/Clinical-and-Genomic-Factors-Associated-with Rugo et al.\u00a0Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. \u00a0Clin Cancer Res, 2025. CCR-25-3040R1.\u00a0https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-3040\/768340\/Real-World-Outcomes-of-Elacestrant-in-ER-HER2-ESR1","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=391065#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=391065"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=391065#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2025\/12\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2025\/12\/Menarini_Industrie_Farmaceutiche_Riunite_Logo.jpg","width":400,"height":121},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=391065#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"Menarini Group \u65bc 2025 \u5e74\u8056\u5b89\u6771\u5c3c\u5967\u4e73\u764c\u7814\u8a0e\u6703\u516c\u4f48 Elacestrant (ORSERDU\u00ae) \u91dd\u5c0d ER+\u3001HER2- \u8f49\u79fb\u6027\u4e73\u764c (mBC) \u60a3\u8005\u7684\u7b2c 2 \u671f\u806f\u5408\u6cbb\u7642\u6578\u64da"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/391065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=391065"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/391065\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/391066"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=391065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=391065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=391065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}